

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



LSHTM Research Online

Momin, BR; Pinheiro, PS; Carreira, H; Li, C; Weir, HK; (2017) Liver cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study. *Cancer*, 123 Su. pp. 5059-5078. ISSN 0008-543X DOI: <https://doi.org/10.1002/cncr.30820>

Downloaded from: <http://researchonline.lshtm.ac.uk/4645628/>

DOI: <https://doi.org/10.1002/cncr.30820>

**Usage Guidelines:**

Please refer to usage guidelines at <https://researchonline.lshtm.ac.uk/policies.html> or alternatively contact [researchonline@lshtm.ac.uk](mailto:researchonline@lshtm.ac.uk).

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

<https://researchonline.lshtm.ac.uk>



**Liver cancer survival in the United States by race and stage  
(2001-2009): findings from the CONCORD -2 study.**

Journal:	<i>Cancer</i>
Manuscript ID	CNCR-17-0457.R1
Wiley - Manuscript type:	Supplement Article
Date Submitted by the Author:	16-May-2017
Complete List of Authors:	Momin, Behnoosh; Centers for Disease Control and Prevention, Division of Cancer Prevention and Control Pinheiro, Paulo; University of Nevada Las Vegas, Carreira, Helena; London School of Hygiene and Tropical Medicine Li, Chunyu; CDC, Weir, H.K.; Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion
Keywords:	liver cancer, population-based survival, NPCR, SEER, cancer control

1  
2  
3 **Liver cancer survival in the United States by race and stage (2001-2009): findings from the**  
4 **CONCORD -2 study.**  
5  
6

7 **Running Title:** Liver cancer survival in the US by race and stage  
8

9 **Authors:** Behnoosh R. Momin, DrPH, MS, MPH<sup>1</sup>; Paulo S. Pinheiro, MD, PhD<sup>2</sup>; Helena  
10 Carreira, MSc<sup>3</sup>, Chunyu Li, MD, PhD, MS<sup>1</sup>, Hannah K Weir, PhD<sup>1</sup>  
11

12 **Affiliations:**

13  
14 <sup>1</sup>Division of Cancer Prevention and Control, Centers for Disease Control and Prevention,  
15 Atlanta, GA

16 <sup>2</sup> Epidemiology and Biostatistics, University of Nevada Las Vegas, Las Vegas, NV

17 <sup>3</sup> Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease  
18 Epidemiology, London School of Hygiene & Tropical Medicine, London, UK  
19

20  
21  
22 **Corresponding Author:**

23 **Dr. Behnoosh R. Momin**

24 4770 Buford Highway, MS F-76

25 Atlanta, GA 30341

26 Telephone: (770) 488-3112

27 Email: [BMomin@cdc.gov](mailto:BMomin@cdc.gov)

28 Fax: (770) 488-4335  
29  
30

31 Number of pages: 20

32 Text words: 3,864

33 Number of figures/tables: 5  
34  
35  
36

37 **Precis:** Some progress has occurred in survival for liver cancer, but 5-year survival remains low,  
38 even for those diagnosed at localized stage. Given the low survival observed in all states, efforts  
39 directed at controlling well-established risk factors, such as hepatitis B may have the greatest  
40 impact on reducing the burden of liver cancer in the United States.  
41  
42

43 **DISCLAIMER:** The findings and conclusions in this report are those of the authors and do not  
44 necessarily reflect the official position of the Centers for Disease Control and Prevention.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Background.** Worldwide, liver cancer is a leading cause of death for both men and women. The number of Americans who are diagnosed with liver cancer and die from it has been rising slowly each year. We examined population-based survival, by state, race, and stage at diagnosis, using data from the CONCORD-2 study. **Methods.** We analyzed data from 37 state-wide registries, covering approximately 80% of the US population, for patients diagnosed during 2001-2009. Survival up to five years was adjusted for background mortality (net survival) using state- and race-specific life tables, and age-standardized using the International Cancer Survival Standard (ICSS) weights. **Results.** Liver cancer was diagnosed overall more often at the localized stage, with blacks being more often diagnosed at distant and regional stages than whites. Overall 5-year net survival was 12.2% in 2001-2003 and 14.8% in 2004-2009. Whites had higher survival than blacks in both calendar periods (11.7% vs. 9.1% and 14.3% vs. 11.4%, respectively). During 2004-2009, 5-year survival was 25.7% for localized stage, 9.5% for regional stage, and 3.5% for distant stage. **Conclusion.** Some progress has occurred in survival for liver cancer, but 5-year survival remains low, even for those diagnosed at localized stage. Efforts directed at controlling well-established risk factors such as hepatitis B may have the greatest impact on reducing the burden of liver cancer in the US.

*Keywords: cancer registries, survival, liver, hepatitis*

## Introduction

Worldwide, liver cancer is the fifth most common cancer among men, the ninth most common cancer among women, and the second most common cause of cancer death for men and women combined (1). Recent reports from North America, Europe, and Japan showed that the incidence of hepatocellular carcinoma (HCC), the most common histological type, is increasing (2-5). The number of Americans who are diagnosed with and die from liver cancer each year has been rising slowly for several decades (6). In 2013, 21,143 men and 8,330 women were diagnosed with liver cancer, and 16,300 men and 7,732 women died from liver cancer (7). According to the 2015 Annual Report to the Nation, United States (US) death rates for most cancer sites declined or were stable from 2003 to 2012 among men and women of each racial and ethnic, except for liver cancer, which increased for most racial and ethnic groups (8). Among men and women, US liver cancer incidence rates were highest among American Indian/Alaskan Natives, followed by Asian Pacific Islanders, and Hispanics. Liver cancer incidence rates among US men were more than twice those among US women (8).

Chronic hepatitis B (HBV), Chronic hepatitis C (HCV), and cirrhosis all contribute to the risks associated with hepatocellular carcinoma. HBV and HCV infections account for an estimated 78% of global HCC cases (9). In addition, excessive alcohol consumption, obesity, rare metabolic disorders, type 2 diabetes mellitus, and non-alcoholic fatty liver disease (NAFLD) are other known risk factors of liver cancer (10). Most cases of HCC are preventable. Methods to reduce the risk of liver cancer include evidence-based strategies or interventions related to the risks associated with hepatitis. Vaccination against hepatitis B infection for all infants at birth

1  
2  
3 and adults who may be at an increased risk, as well as testing for hepatitis C and linking patients  
4  
5 to follow-up care after testing, leads to declines in HCC incidence (8).  
6  
7

8 In contrast to many other cancers, the prognosis of patients with HCC is not highly correlated  
9  
10 with tumor stage. Cirrhosis underlies the neoplasm in most cases and has major impact on the  
11  
12 prognosis of patients with HCC (11). The CONCORD-2 study reported survival for patients  
13  
14 with cancer diagnosed from 1995 through 2009 in 67 countries, and enabled the comparison of  
15  
16 survival of patients in the United States (US) with other countries (12). Liver cancer survival  
17  
18 was low in all countries. The 5-year age-standardized net survival from liver cancer was below  
19  
20 20% everywhere in Europe, in the range 15–19% in North America, and as low as 7–9% in  
21  
22 Mongolia and Thailand. Between 1995-99 and 2005-2009, five-year age-standardized net  
23  
24 survival from liver cancer increased in the United States from 9% to 15%. This could possibly be  
25  
26 due to improved viral hepatitis services and medical management.  
27  
28  
29  
30  
31

32  
33  
34 The purpose of the current study is to expand the CONCORD-2 study by reporting liver cancer  
35  
36 survival in the United States using the largest data set available (80% US coverage), by race and  
37  
38 stage at diagnosis, using available population-based registry data from 37 states. This  
39  
40 information is critical to prioritizing, planning and implementation of cancer control  
41  
42 interventions.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Material and Methods

### Data Source and Variables

Thirty-seven (37) state cancer registries affiliated with the National Program of Cancer Registries (NPCR) or the Surveillance, Epidemiology and End Results (SEER) Programs that participated in the CONCORD-2 study, (12) covering approximately 80% of the US population, agreed to the inclusion of their data in these analyses. We analyzed individual tumor records for 126,261 adults (aged 15-99 years) who were diagnosed with cancer of the liver and intrahepatic bile ducts (ICD-O-3 codes C22.0-C22.1) (13) during 2001-2009 and followed up through December 31, 2009. We included the first primary, invasive cancer of the liver, regardless of whether an individual had a previous cancer. If an individual was diagnosed with two or more cancers of the liver during 2001 through 2009, only the first was considered in the survival analysis.

We grouped patients by year of diagnosis into two calendar periods (2001-2003 and 2004-2009) to reflect changes in the methods used by US registries to collect SEER Summary Stage (SS) 2000 at diagnosis (14). During 2001-2003, most registries coded stage SS2000 directly from the medical records. During 2004-2009, all registries derived SS2000 using the Collaborative Staging System (15).

### *Survival analyses*

We analysed survival by state, race (all, black, white), SS2000 (local, regional, distant, unknown) and calendar period of diagnosis. We estimated net survival up to 5 years after diagnosis, with 95% confidence intervals (CI), using the Pohar Perme estimator (16) of net survival. Net survival can be interpreted as the probability of survival up to a given time since

1  
2  
3 diagnosis, after controlling for other causes of death (background mortality). To control for the  
4 wide differences in background mortality between participating registries, we constructed life  
5 tables (17) of all-cause mortality in the general population of each state from the number of  
6 deaths and the population, by a single year of age, sex, calendar year, and where possible, by  
7 race (black, white), using a flexible Poisson model (18).

8  
9  
10 We estimated net survival using the cohort approach for patients diagnosed in 2001-2003, since  
11 all patients had been followed up for at least five years by December 31, 2009. We used the  
12 complete approach to estimate net survival for patients diagnosed from 2004-2009, because five  
13 years of follow-up data were not available for all patients. Net survival was estimated for five  
14 age groups (15-44, 45-54, 55-64, 65-74, 75-99 years). We obtained age-standardized survival  
15 estimates using the International Cancer Survival Standard (ICSS) weights (19). If two or more  
16 of the five age-specific estimates could not be obtained, we present only the pooled,  
17 unstandardized survival estimates for all ages combined. Unstandardized estimates are italicized  
18 in the tables. Trends, geographic variations and differences in age-standardized survival by race  
19 are presented graphically in bar-charts and funnel plots (20). Funnel plots of net survival for  
20 2001-2003 and 2004-2009 provide insight into the variability of cancer survival in the US by  
21 race and state and show how much a particular survival estimate deviates from the pooled  
22 estimate of US registries (horizontal line) given the precision of each estimate. More details on  
23 data and methods are provided in the accompanying article (21).

## 52 **Results**

53  
54 Liver cancer case distribution by race, state of residence, and stage at diagnosis by calendar  
55 period of diagnosis is reported in Table 1. In 2004-2009, liver cancer was mostly diagnosed at



1  
2  
3 localized stage (overall 41%), followed by regional (24%) and distant (18%). Stage at diagnosis  
4  
5 varied slightly by race, with blacks being most often diagnosed at distant and regional stages  
6  
7 (20% and 26%, respectively, compared to 17% and 24% in whites). However, state-specific  
8  
9 analyses showed that patients with unknown stage at diagnosis ranged from 8% to 30%, which  
10  
11 makes accurate comparisons across race at the national level difficult (Supplemental Table 1).  
12  
13 Between the two calendar periods, there is indication of a shift towards earlier diagnosis of liver  
14  
15 cancer, with an additional 8 percentage points in localized stage and 2 percentage points in  
16  
17 regional stage, and a less than 1 percentage point increase in patients diagnosed with distant  
18  
19 stage. Additionally, there was a substantial decline in the proportion of cases recorded with  
20  
21 unknown stage at diagnosis, from 26% to 17%.  
22  
23  
24  
25  
26  
27  
28

29 Although the overall 5-year age-standardized net survival was low, 12% in 2001-2003 and 15%  
30  
31 in 2004-2009, an improvement between the two calendar periods was observed (Figure 1). Of the  
32  
33 35 states for which an age-standardized estimates were available, net survival increased between  
34  
35 2001-2003 and 2004-2009 in 30 states, while only 5 states showed a decrease. There was  
36  
37 considerable variation by state in 2004-2009 in the 5-year survival, ranging from 8.1% in  
38  
39 Wyoming to 20.9% in Florida (Supplemental Table 2).  
40  
41  
42  
43  
44  
45

46 One-, 3-, and 5-year age-standardized net survival in 2004-2009 was 38%, 21%, 15%,  
47  
48 respectively (Table 2). For each of the three time points, blacks showed lower age-standardized  
49  
50 net survival than whites for all states combined. The difference was most pronounced in the first  
51  
52 year after diagnosis, suggesting that blacks have a lower survival in the short term in addition to  
53  
54 lower survival at five years since diagnosis. Only four states showed considerable in-state racial  
55  
56  
57  
58  
59  
60

1  
2  
3 disparities, all with a survival disadvantage for blacks compared to whites. There was, however,  
4  
5 a 5-year survival improvement for both races from 2001-2003 to 2004-2009, 2.6 percentage  
6  
7 point increase for whites, and 2.3 percentage points for blacks. Five-year age-standardized net  
8  
9 survival was 14.3% for whites and 11.4% for blacks. Overall 5-year survival for all races  
10  
11 combined was 14.8%, higher than both blacks and whites.  
12  
13  
14  
15  
16

17  
18 Five-year age-standardized net survival by stage (Table 3) for 2004-2009 was uniformly low at  
19  
20 26%, 10% and 4% for localized, regional and distant stage, respectively. For localized stage,  
21  
22 increases in survival were observed between 2001-2003 and 2004-2009 with a 2.8 percentage  
23  
24 points for all races, 2.4 percentage points for whites and 5.0 percentage points for blacks. For  
25  
26 regional and distant stages, smaller increases were observed, except that for blacks diagnosed  
27  
28 with regional stage, for whom there was a decline in survival of 1 percentage point. While 5-year  
29  
30 net survival was low in all states, there was considerable variation by stage and state  
31  
32  
33 (Supplemental Table 3).  
34  
35  
36  
37  
38

39  
40 Figure 2 shows funnel plots of net survival for 2001-2003 and 2004-2009, to obtain further  
41  
42 insight into the variability of liver survival in the US, by race and state. Although survival for  
43  
44 liver cancer was generally low in all states in both calendar periods, survival for black patients  
45  
46 was lower than survival for white patients, and in most states it was lower than the pooled U.S.  
47  
48 value.  
49  
50

## 51 **Discussion**

52  
53  
54 This study reports the most comprehensive comparison of trends in the United States in 5-year  
55  
56 survival for liver cancer, using recent population-based data. The 5-year age-standardized net  
57  
58  
59  
60

1  
2  
3 survival for liver cancer reported in this analysis was low (15%) for the most recent period, but  
4 slightly higher than in 2001-2003 (12%). This slight increase may be partially explained by the  
5 increased proportion of patients diagnosed at localized stage who showed improved survival in  
6 the most recent years. Five-year survival in the US is slightly lower but still closely aligned with  
7 the 5-year survival estimates of Canada (17.7% [16.8-18.7%], 2005-2009) and slightly higher  
8 than survival in the United Kingdom (9.3% [8.7-9.9%], 2005-2009) (12). This study noted some  
9 variations in survival by state, race, and sex. Whites had higher survival than blacks in both  
10 calendar periods. Additionally, white women showed a survival rate that was 2.5 percentage  
11 points higher than white men, and black women showed a survival rate that was 5.5 percentage  
12 points higher than black men. While our findings report a survival advantage for women, this is  
13 in contrast to those reported for Europe in the late 1990s (22). Micheli and colleagues reported  
14 an advantage for women for 11 of the 26 cancer sites; this advantage was not reported for liver  
15 cancer. This difference may reflect a difference in US and European populations. Regardless of  
16 state, variations in liver cancer survival by race and gender are unknown, liver cancer is  
17 uniformly fatal across all populations. Early diagnosis for liver cancer is challenging, since  
18 many of the symptoms associated with this disease do not present until later stages. In addition,  
19 due to the location of the liver beneath the rib cage, liver tumors are difficult to detect.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 This study suggests there is some improvement in liver cancer survival. Advances in treatment  
47 strategies likely contributed to this improvement. Surgical resection, liver transplantation, and  
48 ablation are associated with best long-term survival. Surgical resection is usually performed in  
49 patients with localized HCC and sufficient preserved liver function. Liver transplantation is the  
50 best option for patients with decompensated cirrhosis and a solitary lesion (<5 cm) or early  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 multifocal disease ( $\leq 3$  lesions,  $\leq 3$  cm in diameter) (23). When liver resection or transplantation is  
4  
5 feasible, ablation may be used, particularly for patients with early-stage HCC that is centrally  
6  
7 located in the liver. Disparities in access to and receipt of appropriate surgical care may play an  
8  
9 essential role for the racial differences we observed in liver cancer survival. Studies have shown  
10  
11 that African Americans and Asians with localized HCC were significantly less likely to receive a  
12  
13 transplant compared to their white counterpart (24). In addition, African American patients were  
14  
15 found to be younger and have a more advanced stage of disease than white patients, and were  
16  
17 also more likely to die while waiting for a transplant (25). However, survival disparities by race  
18  
19 may not be explained by differences in care only. Artinyan and colleagues reported that racial  
20  
21 differences in survival remained significant among patients who received liver transplantation  
22  
23  
24  
25  
26  
27 (26).

### 31 *Clinical Implications*

32  
33 To improve liver cancer survival, adherence to evidence-based treatment protocols among all  
34  
35 populations, as well as other factors including biologic factors, response to therapy, patient  
36  
37 comorbidities, post-treatment follow-up and care, and tumor recurrence all need to be  
38  
39 considered. Increased recruitment of non-white populations to liver cancer clinical trials may  
40  
41 help alleviate racial differences in survival and improve the understanding of race-based  
42  
43 differences in cancer biology (27). HBV or HCV can cause persistent active hepatitis and  
44  
45 hepatic fibrosis, which lead to the development of HCC and also has major impact on the  
46  
47 prognosis of patients with HCC by affecting the rate of recurrence after surgery (28-30).  
48  
49 Interferon therapy has shown to be beneficial for patients with hepatitis virus-associated HCC  
50  
51 and can improve their outcome after curative resection (31).  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Cancer Control Implications*

Given that most liver cancers are preventable (CDC), cancer control efforts and resources that support preventing infection and promoting viral hepatitis services should be prioritized (32-33). Approximately 22% of HCC among those aged 65 years or older in the United States is attributed to HCV, (10) and an estimated 1.6 million persons will be eligible for HCV treatment by 2020 (34). Antiviral therapies for hepatitis B and hepatitis C can help prevent liver cancer, and also result in decreased neuroinflammation in the liver and over time cause reversal of fibrosis, which also leads to decreased HCC risk (35). In 2012, the CDC recommended one-time HCV testing for persons born during 1945–1965 (aged 47–67 years in 2012) (36). The following year, the US Preventive Services Task Force issued similar recommendations (37). According to the National Academies of Science, Engineering, and Medicine (38), limited public and provider awareness, as well as limited public resource allocation are the primary underlying causes of high rates of chronic hepatitis B and C in the United States (38). In the U.S., Asians have the highest incidence of HBV (39). However, for other populations (non-Asians), the incidence of HBV is not as much a concern as the incidence of HCV, which assumes a bigger role in the etiology of liver cancer (40). For the latter group, the patterns among immigrants are consistent and gender specific, with a higher incidence and mortality for males when coming to the U.S., but females having stabilized or slightly decreased rates. This has been shown for different populations (Hispanics and non-Hispanic Blacks) (41-43). CDC’s National Comprehensive Cancer Control Program (NCCCCP) is currently working on the development and implementation of an action plan that would facilitate greater implementation and uptake of strategies and interventions to address liver cancer within selected pilot programs that have a high liver cancer

1  
2  
3 burden. The action plan will contain interventions specific to increasing support for vaccine-  
4 based strategies to eliminate HBV transmission, and development of prevention and health  
5 services that include screening for HBV and HCV infections linked to appropriate medical  
6 management and care (in alignment with recommendations), community education about HBV  
7 and HCV, and the improvement of viral hepatitis surveillance. Improved surveillance for HBV  
8 and patients with HCV-related cirrhosis has the potential to result in the detection of more  
9 cancers at a localized stage when surgery may be possible and more beneficial (44).  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

### 22 ***Strength and Limitations***

23  
24 This analysis has several strengths, including that it includes a very large number of US states,  
25 making it the most geographically-comprehensive survival study to our knowledge. Also, the  
26 sophisticated and complex methodology takes into account the competing risks of death that are  
27 higher for elderly than for younger cancer patients. Finally, more than 70% of all cases included  
28 in this analysis were morphologically verified, contributing to the high quality of the data used.  
29  
30  
31  
32  
33

34 A limitation of our analysis is that some stage and race categories had missing data or small  
35 numbers. The small black population in some states precluded the construction of life tables for  
36 the black population in these states; therefore the state-specific life tables for all races combined  
37 were used instead. Additionally, data on populations with a higher burden of liver cancer,  
38 including Asian/Pacific Islanders and Hispanics, were not collected or analyzed in this study.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

### 50 ***Conclusions***

51  
52 Cancer incidence in the United States is expected to increase greatly due to demographic changes  
53 such as an aging population and a larger proportion of individuals from racial/ethnic groups; it is  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

estimated that liver cancer will rank the second highest of increase (59%) between 2010 through 2030 among all cancer sites (45). This analysis suggests some progress in five-year survival for liver cancer in the U.S.; however, there is still much more work that needs to be done in order to reduce the burden of this cancer. Improvements in surveillance, prevention and detection of HBV and HCV infection may have the greatest potential of leading to earlier detection resulting in increased survival.

## Figures and Tables

Figure 1. Liver cancer: 5-year age-standardized net survival (%) for adults (15-99 years) diagnosed during 2001-2003 and 2004-2009, and absolute change (%): states grouped by U.S. Census Region.

Note: Data from 37 statewide cancer registries (covering 80.6% of the population) are ranked within U.S. Census Region by the survival estimate for 2004-2009. Dark colors denote states affiliated with the National Program of Cancer Registries (NPCR); pale colors denote states affiliated with the Surveillance, Epidemiology and End Results (SEER) Program; \* denotes states affiliated with both federal surveillance programs. Change (%) not plotted if a survival estimate was not available for one calendar period or one or more estimates was not age-standardized.

Figure 2. Liver cancer: 5-year age-standardized net survival (%) for adults (15-99 years), by state, race and calendar period of diagnosis.

Note: the pooled (US) survival estimate for each calendar period is shown by the horizontal (solid) line with corresponding 95.0% and 99.8% control limits (dotted lines).

Supplemental Table 1. Liver cancer: number of cases for adults (15-99 years) diagnosed during 2001-2003 and 2004-2009 and distribution (%) by SEER Summary Stage 2000 at diagnosis, race and calendar period of diagnosis.

Note: NPCR indicates National Program of Cancer Registries; SEER indicates Surveillance, Epidemiology, and End Results program. Information on stage was not available for two states (Maryland and Wisconsin), or for Rhode Island for cases diagnosed during 2004- 2009. This is the same information that appears in Table 1.

Supplemental Table 2. Liver cancer: 1-, 3- and 5-years age-standardized net survival (%) for adults (15-99 years) diagnosed during 2001-2003 and 2004-2009, by race and calendar period of diagnosis.

Note: NPCR indicates National Program of Cancer Registries; SEER indicates Surveillance, Epidemiology, and End Results program. Unstandardized estimates are italicized.



1  
2  
3 Supplemental Table 3. Liver cancer: 5-year age-standardized net survival (%) for adults (15-99  
4 years) diagnosed during 2001-2003 and 2004-2009, by SEER Summary Stage 2000 at  
5 diagnosis, race and calendar period.  
6  
7

8 Note: NPCR indicates National Program of Cancer Registries; SEER indicates Surveillance,  
9 Epidemiology, and End Results program. Information on stage was not available for two states  
10 (Maryland and Wisconsin), or for Rhode Island for cases diagnosed during 2004- 2009.  
11  
12  
13  
14

15 Unstandardized estimates are italicized.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1. Liver cancer: number of cases for males and females (15-99 years) diagnosed 2001-2009 and distribution (%) by SEER Summary Stage 2000 (SS2000) at diagnosis, by race and calendar period of diagnosis.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

	2001-2003			2004-2009		
SS2000	All races	White	Black	All races	White	Black
No. of patients	33,690	25,500	4,225	92,571	69,374	13,002
Localized (%)	33.4	33.2	30.4	41.0	40.9	38.8
Regional (%)	22.4	21.6	23.6	24.4	23.8	25.9
Distant (%)	18.4	18.2	20.4	17.6	17.4	19.8
Unknown (%)	25.8	27.0	25.6	17.0	17.8	15.5

Table 2. Liver cancer: age-standardized net survival (%) at 1-, 3- and 5-years for females (15-99 years) diagnosed 2001-2009, by race and calendar period of diagnosis.

Year	2001-2003						2004-2009					
	All races		White		Black		All races		White		Black	
	NS (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI
1	31.8	31.3 - 32.3	31.7	31.1 - 32.3	27.3	25.8 - 28.9	38.2	37.8 - 38.5	38.0	37.6 - 38.4	32.9	31.9 - 33.9
3	16.2	15.8 - 16.7	15.7	15.3 - 16.2	13.2	11.9 - 14.4	20.5	20.1 - 20.8	19.9	19.5 - 20.3	16.5	15.5 - 17.5
5	12.2	11.8 - 12.5	11.7	11.3 - 12.1	9.1	8.0 - 10.2	14.8	14.4 - 15.2	14.3	13.8 - 14.8	11.4	10.3 - 12.5

Table 3. Liver cancer: 5-year age-standardized net survival (%) for females (15-99 years) diagnosed 2001-2009, by SEER Summary Stage (SS2000) at diagnosis, race and calendar period of diagnosis.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

	2001-2003											2004-2009													
	All races				White				Black			All races				White				Black					
	N				NS (%)				N			NS (%)				N				N			NS (%)		
All stages	12	11	-	12.5	11.7	11	-	12.1	9	8	-	10.2	14	14	-	15.2	14	13	-	14	11	10	-	12	
Localized	22	22	-	23.8	22.4	21	-	23.4	15	13	-	18.2	25	24	-	26.5	24	23	-	25	20	18	-	23	
Regional	8	7	-	9.0	7.6	6	-	8.4	8	6	-	10.4	9	8	-	10.2	9	8	-	9	7	5	-	8	
Distant	2	2	-	3.3	2.4	2	-	2.9	2	1	-	3.8	3	3	-	4.0	2	2	-	3	3	2	-	5	
Unknown	8	7	-	8.9	7.9	7	-	8.7	7	5	-	8.8	8	8	-	9.6	9	8	-	9	6	4	-	7	
	2	6				2			0	3			2				0	1		8	2	6		8	

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**References:**

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.
2. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. *Cancer Res* 1987;47:4967–4972. S300 E. JENNY HEATHCOTE GASTROENTEROLOGY Vol. 127, No. 5
3. Taylor-Robinson SD, Foster GR, Arora S, Gargreaves S, Thomas HC. Increase in primary liver cancer in the UK 1979-1994. *Lancet* 1997;350:1142–1143.
4. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. *Lancet* 1998;351:214–215.
5. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. *Ann Intern Med* 2003;139:817–823.
6. Weir, H. K., Thompson, T. D., Soman, A., Møller, B. and Leadbetter, S. (2015), The past, present, and future of cancer incidence in the United States: 1975 through 2020. *Cancer*, 121: 1827–1837. doi:10.1002/cncr.29258.
7. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2013 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2016. Available at: [www.cdc.gov/uscs](http://www.cdc.gov/uscs), accessed February 3, 2017. <http://www.cdc.gov/cancer/liver/index.htm>
8. Ryerson AB, Ehemann CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. Annual report to the nation on the status of cancer, 1975–2012, featuring the increasing incidence of liver cancer. *Cancer* 2016;122(9):1312–37.
9. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *J Hepatol* 2006;45:529--38.
10. Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, El-Serag HB, et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. *Am J Gastroenterol*. 2013;108(8):1314-21. doi: 10.1038/ajg.2013.160. Epub 2013 Jun 11.
11. Gretten TF, Papendorf F, Bleck JS, et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. *British Journal of Cancer*. 2005;92(10):1862-1868. doi:10.1038/sj.bjc.6602590.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
12. Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). *Lancet*. 2015;385(9972):977-1010. SEER 2007 Multiple Primary and Histology Coding Rules. <http://seer.cancer.gov/tools/mphrules/>.
  13. Fritz AG, Percy C, Jack A, Shanmugaratnam K, Sobin LH, Parkin DM, Whelan SL, eds. International Classification of Diseases for Oncology (ICD-O). 3rd edn. Geneva: World Health Organization; 2000.
  14. Young JL, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA. SEER Summary Staging Manual - 2000: Codes and Coding Instructions. NIH Pub. No. 01-4969. Bethesda, MD: National Cancer Institute; 2001.
  15. Surveillance Epidemiology and End Results program. Collaborative Stage. Bethesda, MD: National Cancer Institute, 2004. <http://seer.cancer.gov/tools/collabstaging/> (accessed 1 April 2016).
  16. Pohar Perme M, Stare J, Estève J. On estimation in relative survival. *Biometrics* 2012; 68: 113-20.
  17. Spika D, Rachet B, Bannon F, Woods LM, Maringe C, Bonaventure A, Coleman MP, Allemani C. Life tables for the CONCORD-2 study. London: CONCORD Central Analytic Team, 2015. <http://csg.lshtm.ac.uk/tools-analysis/life-tables/> (accessed 1 April 2016).
  18. Rachet B, Maringe C, Woods LM, Ellis L, Spika D, Allemani C. Multivariable flexible modelling for estimating complete, smoothed life tables for sub-national populations. *BMC Public Health* 2015; 15.
  19. Corazziari I, Quinn MJ, Capocaccia R. Standard cancer patient population for age standardising survival ratios. *Eur J Cancer* 2004; 40: 2307-16.
  20. Quaresma M, Coleman MP, Rachet B. Funnel plots for population-based cancer survival: principles, methods and applications. *Stat Med* 2014; 33: 1070-80.
  21. Allemani C, Harewood R, Johnson C, et al. Population-based cancer survival in the US: data, quality control and statistical methods. *Cancer*. 2017.
  22. Micheli A, Ciampichinia R, Oberaigner W, et. al. The EURO CARE Working Group. European Journal of Cancer. The advantage of women in cancer survival: An analysis of EURO CARE-4 data A.
  23. Bruix J, Sherman M; American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma: an update. *Hepatology* 53 (3): 1020-2, 2011. [PUBMED Abstract]


- 1  
2  
3  
4  
5 24. Siegel AB<sup>1</sup>, McBride RB, El-Serag HB, Hershman DL, Brown RS Jr, Renz JF, Emond J,  
6 Neugut AI. Racial disparities in utilization of liver transplantation for hepatocellular  
7 carcinoma in the United States, 1998-2002. *Am J Gastroenterol*. 2008 Jan;103(1):120-7.  
8 Epub 2007 Nov 15.  
9  
10  
11  
12 25. Reid AE<sup>1</sup>, Resnick M, Chang Y, Buerstatte N, Weissman JS. Disparity in use of orthotopic  
13 liver transplantation among blacks and whites. *Liver Transpl*. 2004 Jul;10(7):834-41.  
14  
15  
16 26. Artinyan A<sup>1</sup>, Mailey B, Sanchez-Luege N, Khalili J, Sun CL, Bhatia S, Wagman LD, Nissen  
17 N, Colquhoun SD, Kim J. Race, ethnicity, and socioeconomic status influence the survival of  
18 patients with hepatocellular carcinoma in the United States. *Cancer*. 2010 Mar 1;116(5):1367-77.  
19 doi: 10.1002/cncr.24817.  
20  
21  
22  
23 27. Carey LA, Perou CM, Livasy CA, et al. Race, Breast Cancer Subtypes, and Survival in the  
24 Carolina Breast Cancer Study. *JAMA*. 2006;295(21):2492-2502. doi:10.1001/jama.295.21.2492.  
25  
26  
27 28. Kubo S, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, Ikebe T, Yamamoto T, Wakasa K,  
28 Nishiguchi S, Kuroki T, Kinoshita H. Risk factors for recurrence after resection of hepatitis C  
29 virus-related hepatocellular carcinoma. *World J Surg*. 2000 Dec;24(12):1559-65.  
30  
31  
32  
33  
34 29. Kubo S<sup>1</sup>, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, Yamamoto T, Ikebe T, Wakasa K,  
35 Nishiguchi S, Kinoshita H. Effect of viral status on recurrence after liver resection for patients  
36 with hepatitis B virus-related hepatocellular carcinoma. *Cancer*. 2000 Mar 1;88(5):1016-24.  
37  
38  
39  
40 30. Wu JC<sup>1</sup>, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, Huo TI, Sheen IJ, Lee SD, Lui  
41 WY. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. *J*  
42 *Hepatol*. 2009 Nov;51(5):890-7. doi: 10.1016/j.jhep.2009.07.009. Epub 2009 Jul 23.  
43  
44  
45 31. Kubo S<sup>1</sup>, Takemura S, Sakata C, Urata Y, Uenishi T. Adjuvant therapy after curative  
46 resection for hepatocellular carcinoma associated with hepatitis virus. *Liver Cancer*. 2013  
47 Jan;2(1):40-6. doi: 10.1159/000346214.  
48  
49  
50 32. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The  
51 prevalence of hepatitis C virus infection in the United States, 1999 through 2002. *Ann Intern*  
52 *Med*. 2006;144(10):705-14.  
53  
54  
55 33. Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis - United States, 2007.  
56 *MMWR Surveill Summ*. 2009;58(3):1-27.  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
34. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. *Ann Intern Med.* 2015;162(6):397-406. doi: 10.7326/M14-1336.
35. Lok, Anna Suk-Fong. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma? *Journal of Gastroenterology and Hepatology*
36. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. *MMWR Recomm Rep.* 2012;61(RR-4):1-32.
37. Moyer VA. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2013;159(5):349-57. doi: 10.7326/0003-4819-159-5-201309030-00672.
38. IOM (Institute of Medicine). 2010. *Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C.* Washington, DC: The National Academies Press.
39. Moore MS, Ivanina E, Bornschlegel K, Qiao B, Schymura MJ, Laraque F. Hepatocellular Carcinoma and Viral Hepatitis in New York City. *Clinical Infectious Diseases.* 2016:ciw605.
40. El-Serag HB, Lau M, Eschbach K, Davila J, Goodwin J. Epidemiology of hepatocellular carcinoma in Hispanics in the United States. *Arch Intern Med.* 2007;167(18):1983-9.
41. Pinheiro PS, Sherman RL, Trapido EJ, Fleming LE, Huang Y, Gomez-Marin O, et al. Cancer incidence in first generation U.S. Hispanics: Cubans, Mexicans, Puerto Ricans, and new Latinos. *Cancer Epidemiol Biomarkers Prev.* 2009 Aug;18(8):2162-9.
42. Pinheiro PS, Callahan KE, Siegel RL, Jin H, Morris CR, Trapido EJ, et al. Cancer Mortality in Hispanic Ethnic Groups. *Cancer Epidemiol Biomarkers Prev.* 2017 Mar;26(3):376-82.
43. Pinheiro PS, Callahan KE, Ragin CR, Hage RW, Hylton T, Kobetz EN. Black heterogeneity in cancer mortality: US-Blacks, Haitians, and Jamaicans. *Cancer Control.* 2016;23(4):347.
44. El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and how? Editorial. *Ther Adv Gastroenterol.* 2011;4 (1):5-10. DOI: 10.1177/1756283X10385964
45. Smith BD1, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. *J Clin Oncol.* 2009 Jun 10;27(17):2758-65. doi: 10.1200/JCO.2008.20.8983. Epub 2009 Apr 29.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2

86x60mm (600 x 600 DPI)

Stage	2001-2003			2004-2009			
	All races	White	Black	All races	White	Black	
<b>UNITED STATES</b>							
No. of patients	33,690	25,500	4,225	92,571	69,374	13,002	
Localized (%)	33.4	33.2	30.4	41.0	40.9	38.8	
Regional (%)	22.4	21.6	23.6	24.4	23.8	25.9	
Distant (%)	18.4	18.2	20.4	17.6	17.4	19.8	
Unknown (%)	25.8	27.0	25.6	17.0	17.8	15.5	
<b>NORTHEAST</b>							
<b>New England</b>							
Connecticut (SEER)	No. of patients	492	421	53	1,411	1,170	164
	Localized (%)	36.6	36.8	35.8	41.2	40.8	42.1
	Regional (%)	17.5	16.6	22.6	24.9	23.9	32.3
	Distant (%)	19.5	19.5	17.0	18.9	19.4	15.9
	Unknown (%)	26.4	27.1	24.5	15.0	15.9	9.8
Massachusetts (NPCR)	No. of patients	998	827	75	2,741	2,299	178
	Localized (%)	34.4	34.0	28.0	40.9	41.0	33.7
	Regional (%)	25.4	24.9	32.0	26.4	26.1	32.6
	Distant (%)	15.8	16.2	14.7	16.7	16.8	15.7
	Unknown (%)	24.4	24.9	25.3	16.0	16.1	18.0
New Hampshire (NPCR)	No. of patients	133	118	-	355	332	-
	Localized (%)	24.8	24.6	66.7	35.5	35.5	50.0
	Regional (%)	24.1	21.2	33.3	27.9	28.6	50.0
	Distant (%)	16.5	17.8	0.0	17.2	17.8	0.0
	Unknown (%)	34.6	36.4	0.0	19.4	18.1	0.0
Rhode Island (NPCR)	No. of patients	176	161	10	409	353	32
	Localized (%)	29.5	29.8	30.0	-	-	-
	Regional (%)	29.0	28.6	40.0	-	-	-
	Distant (%)	15.3	13.7	30.0	-	-	-
	Unknown (%)	26.1	28.0	0.0	-	-	-
<b>Mid Atlantic</b>							
New Jersey (NPCR/SEER)	No. of patients	1,421	1,093	199	3,339	2,587	488
	Localized (%)	30.6	29.1	33.2	41.6	41.0	40.8
	Regional (%)	19.7	19.7	21.1	21.2	21.3	20.7
	Distant (%)	20.1	20.4	21.6	16.4	16.2	18.0
	Unknown (%)	29.6	30.8	24.1	20.8	21.5	20.5
New York (NPCR)	No. of patients	3,465	2,458	578	8,877	6,052	1,670
	Localized (%)	28.1	27.8	23.9	41.4	40.4	39.2
	Regional (%)	21.0	20.5	24.2	23.9	24.0	25.5
	Distant (%)	17.7	17.4	19.7	18.6	18.7	21.0
	Unknown (%)	33.2	34.3	32.2	16.1	16.9	14.4
Pennsylvania (NPCR)	No. of patients	2,004	1,569	322	5,026	3,957	821
	Localized (%)	31.2	31.2	29.2	42.6	41.7	43.7
	Regional (%)	24.5	25.7	20.8	26.5	26.3	28.7
	Distant (%)	20.5	20.0	23.6	18.2	18.7	16.9
	Unknown (%)	23.8	23.0	26.4	12.8	13.3	10.6
<b>SOUTH</b>							
<b>South Atlantic</b>							
Delaware (NPCR)	No. of patients	106	87	16	310	218	81
	Localized (%)	41.5	41.4	43.8	45.8	47.2	40.7
	Regional (%)	21.7	17.2	43.8	26.1	25.7	27.2
	Distant (%)	16.0	17.2	12.5	19.7	19.3	22.2
	Unknown (%)	20.8	24.1	0.0	8.4	7.8	9.9
Florida (NPCR)	No. of patients	2,721	2,337	276	7,339	6,063	946
	Localized (%)	29.1	29.3	26.4	38.9	39.6	33.4
	Regional (%)	19.8	19.3	25.4	23.3	23.0	26.6
	Distant (%)	20.3	20.1	22.8	16.5	16.0	20.0
	Unknown (%)	30.8	31.4	25.4	21.3	21.3	20.0
Georgia (NPCR/SEER)	No. of patients	813	540	217	2,698	1,798	764
	Localized (%)	35.9	36.3	33.6	43.7	44.4	42.3
	Regional (%)	21.5	20.4	24.0	25.8	25.0	27.7
	Distant (%)	19.8	20.6	19.4	18.9	17.7	21.9
	Unknown (%)	22.8	22.8	23.0	11.6	12.9	8.1

## Cancer

	Stage	2001-2003			2004-2009		
		All races	White	Black	All races	White	Black
Maryland (NPCR)	No. of patients	657	411	192	1,524	901	517
	Localized (%)	-	-	-	-	-	-
	Regional (%)	-	-	-	-	-	-
	Distant (%)	-	-	-	-	-	-
	Unknown (%)	-	-	-	-	-	-
North Carolina (NPCR)	No. of patients	934	695	197	2,873	2,094	631
	Localized (%)	38.1	41.3	28.9	41.8	41.8	40.9
	Regional (%)	21.1	20.4	21.8	25.5	25.6	26.0
	Distant (%)	17.8	16.3	21.8	17.9	17.3	18.9
	Unknown (%)	23.0	22.0	27.4	14.8	15.3	14.3
South Carolina (NPCR)	No. of patients	485	352	118	1,339	951	347
	Localized (%)	36.9	38.9	30.5	40.0	40.9	37.5
	Regional (%)	17.5	18.2	16.1	22.3	22.0	23.1
	Distant (%)	15.5	15.1	16.1	17.8	17.4	19.9
	Unknown (%)	30.1	27.8	37.3	19.9	19.8	19.6
West Virginia (NPCR)	No. of patients	230	220	-	562	531	27
	Localized (%)	25.7	25.9	25.0	35.6	35.6	33.3
	Regional (%)	16.1	16.4	0.0	21.4	21.7	14.8
	Distant (%)	19.1	19.1	12.5	15.1	14.5	29.6
	Unknown (%)	39.1	38.6	62.5	27.9	28.2	22.2
<b>East South Central</b>							
Alabama (NPCR)	No. of patients	514	381	119	1,408	1,068	317
	Localized (%)	30.2	29.7	30.3	43.4	44.7	38.8
	Regional (%)	21.6	21.5	20.2	20.7	19.9	23.7
	Distant (%)	18.7	19.7	16.8	17.0	16.0	19.9
	Unknown (%)	29.6	29.1	32.8	18.8	19.4	17.7
Kentucky (NPCR/SEER)	No. of patients	466	418	41	1,353	1,207	129
	Localized (%)	35.8	35.4	36.6	43.7	42.8	50.4
	Regional (%)	21.2	20.6	31.7	23.7	24.3	17.8
	Distant (%)	17.2	17.7	14.6	18.6	17.9	24.8
	Unknown (%)	25.8	26.3	17.1	14.1	15.0	7.0
Mississippi (NPCR)	No. of patients	128	91	28	899	622	251
	Localized (%)	35.9	37.4	35.7	38.2	41.0	32.3
	Regional (%)	20.3	19.8	14.3	29.0	26.5	34.3
	Distant (%)	22.7	24.2	21.4	20.2	19.3	21.9
	Unknown (%)	21.1	18.7	28.6	12.6	13.2	11.6
Tennessee (NPCR)	No. of patients	177	149	22	1,805	1,417	334
	Localized (%)	40.7	42.3	36.4	46.1	46.4	42.8
	Regional (%)	22.6	24.2	9.1	22.7	22.4	23.1
	Distant (%)	19.2	16.1	36.4	16.8	16.7	19.8
	Unknown (%)	17.5	17.4	18.2	14.4	14.5	14.4
<b>West South Central</b>							
Louisiana (NPCR/SEER)	No. of patients	694	464	211	1,739	1,066	609
	Localized (%)	41.2	43.8	37.0	49.7	50.3	47.5
	Regional (%)	24.9	24.6	25.1	23.1	22.1	25.0
	Distant (%)	18.0	15.5	22.7	18.0	17.4	19.2
	Unknown (%)	15.9	16.2	15.2	9.3	10.2	8.4
Oklahoma (NPCR)	No. of patients	425	319	37	1,280	979	85
	Localized (%)	28.7	28.5	18.9	37.3	39.0	31.8
	Regional (%)	15.3	14.4	16.2	20.0	19.0	24.7
	Distant (%)	21.9	23.2	24.3	19.8	19.1	24.7
	Unknown (%)	34.1	33.9	40.5	23.0	22.9	18.8
Texas (NPCR)	No. of patients	3,543	2,944	405	10,265	8,253	1,422
	Localized (%)	34.1	34.2	33.1	41.5	42.7	35.6
	Regional (%)	17.3	16.5	22.2	20.7	19.7	26.1
	Distant (%)	17.6	17.4	20.0	17.2	16.7	19.9
	Unknown (%)	31.0	31.8	24.7	20.6	20.9	18.4

Stage		2001-2003			2004-2009		
		All races	White	Black	All races	White	Black
<b>MIDWEST</b>							
<b>East North Central</b>							
Michigan (NPCR/SEER)	No. of patients	1,412	1,072	278	3,485	2,559	755
	Localized (%)	30.5	30.1	31.3	35.0	35.0	34.8
	Regional (%)	19.6	18.9	21.9	16.2	16.1	15.8
	Distant (%)	20.0	19.1	24.8	19.3	18.8	21.5
	Unknown (%)	30.0	31.8	21.9	29.5	30.1	27.9
Ohio (NPCR)	No. of patients	1,301	1,036	215	3,476	2,735	634
	Localized (%)	28.5	29.0	26.5	35.5	34.8	36.1
	Regional (%)	17.8	18.0	17.2	21.9	20.7	26.7
	Distant (%)	15.5	15.6	14.9	15.0	15.1	14.8
	Unknown (%)	38.1	37.5	41.4	27.6	29.4	22.4
Wisconsin (NPCR)	No. of patients	660	587	45	1,661	1,370	158
	Localized (%)	-	-	-	-	-	-
	Regional (%)	-	-	-	-	-	-
	Distant (%)	-	-	-	-	-	-
	Unknown (%)	-	-	-	-	-	-
<b>West North Central</b>							
Iowa (SEER)	No. of patients	295	276	-	861	795	28
	Localized (%)	30.2	30.1	40.0	36.4	37.0	32.1
	Regional (%)	28.8	29.7	20.0	30.0	29.1	42.9
	Distant (%)	20.3	19.9	20.0	20.6	20.0	25.0
	Unknown (%)	20.7	20.3	20.0	13.1	14.0	0.0
Nebraska (NPCR)	No. of patients	243	217	11	595	513	44
	Localized (%)	33.3	32.7	54.5	34.6	35.3	29.5
	Regional (%)	22.2	21.7	18.2	31.1	31.0	31.8
	Distant (%)	15.6	14.7	18.2	17.8	16.6	25.0
	Unknown (%)	28.8	30.9	9.1	16.5	17.2	13.6
<b>WEST</b>							
<b>Mountain</b>							
Colorado (NPCR)	No. of patients	521	436	32	1,442	1,255	74
	Localized (%)	37.0	37.8	25.0	41.9	41.5	33.8
	Regional (%)	21.9	20.9	34.4	25.0	24.5	27.0
	Distant (%)	20.2	19.5	25.0	19.2	19.7	25.7
	Unknown (%)	20.9	21.8	15.6	13.9	14.3	13.5
Idaho (NPCR)	No. of patients	92	88	-	332	316	-
	Localized (%)	33.7	33.0	-	38.0	38.0	-
	Regional (%)	29.3	30.7	-	26.2	26.9	-
	Distant (%)	18.5	17.0	-	21.1	21.5	-
	Unknown (%)	18.5	19.3	-	14.8	13.6	-
Montana (NPCR)	No. of patients	76	67	-	232	191	-
	Localized (%)	25.0	23.9	100.0	40.5	42.4	-
	Regional (%)	23.7	23.9	0.0	31.5	29.8	-
	Distant (%)	10.5	11.9	0.0	17.2	17.8	-
	Unknown (%)	40.8	40.3	0.0	10.8	9.9	-
New Mexico (SEER)	No. of patients	332	293	-	911	783	13
	Localized (%)	42.8	43.3	33.3	42.7	42.5	38.5
	Regional (%)	16.3	14.7	0.0	16.9	17.2	15.4
	Distant (%)	19.3	19.8	33.3	18.8	19.2	30.8
	Unknown (%)	21.7	22.2	33.3	21.6	21.1	15.4
Utah (SEER)	No. of patients	139	117	-	456	405	11
	Localized (%)	46.0	46.2	-	44.5	45.4	45.5
	Regional (%)	24.5	21.4	-	30.9	30.1	18.2
	Distant (%)	15.1	17.1	-	14.5	14.3	18.2
	Unknown (%)	14.4	15.4	-	10.1	10.1	18.2
Wyoming (NPCR)	No. of patients	41	38	-	131	125	-
	Localized (%)	17.1	18.4	0.0	43.5	44.0	-
	Regional (%)	17.1	18.4	0.0	22.9	23.2	-
	Distant (%)	14.6	15.8	0.0	13.7	12.8	-
	Unknown (%)	51.2	47.4	100.0	19.8	20.0	-

## Cancer

Stage	2001-2003			2004-2009			
	All races	White	Black	All races	White	Black	
<b>Pacific</b>							
Alaska (NPCR)	No. of patients	100	62	-	238	141	16
	Localized (%)	28.0	22.6	50.0	43.7	41.8	56.3
	Regional (%)	22.0	21.0	25.0	23.9	23.4	18.8
	Distant (%)	18.0	16.1	0.0	16.4	14.9	6.3
	Unknown (%)	32.0	40.3	25.0	16.0	19.9	18.8
California (NPCR/SEER)	No. of patients	6,206	4,044	456	16,772	11,251	1,285
	Localized (%)	38.2	38.0	32.9	43.1	42.7	38.7
	Regional (%)	27.4	26.1	32.2	28.0	27.4	31.1
	Distant (%)	18.1	17.8	21.3	17.5	17.7	21.0
	Unknown (%)	16.3	18.1	13.6	11.5	12.2	9.2
Hawaii (SEER)	No. of patients	364	49	-	818	185	11
	Localized (%)	40.7	38.8	100.0	41.7	36.2	18.2
	Regional (%)	34.3	36.7	0.0	27.9	28.1	27.3
	Distant (%)	19.8	16.3	0.0	18.2	20.0	45.5
	Unknown (%)	5.2	8.2	0.0	12.2	15.7	9.1
Oregon (NPCR)	No. of patients	430	362	-	1,440	1,219	39
	Localized (%)	24.9	24.9	33.3	36.6	36.3	35.9
	Regional (%)	26.0	24.3	33.3	29.7	28.9	25.6
	Distant (%)	18.6	19.1	11.1	18.4	18.5	15.4
	Unknown (%)	30.5	31.8	22.2	15.3	16.3	23.1
Washington (NPCR/SEER)	No. of patients	896	701	34	2,169	1,613	119
	Localized (%)	37.9	37.1	41.2	38.7	36.9	48.7
	Regional (%)	33.4	31.7	44.1	31.0	31.1	31.9
	Distant (%)	14.4	14.8	11.8	18.9	19.4	16.8
	Unknown (%)	14.3	16.4	2.9	11.3	12.6	2.5

Years	2001-2003						2004-2009					
	All races		White		Black		All races		White		Black	
	NS	95% CI	NS	95% CI	NS	95% CI	NS	95% CI	NS	95% CI	NS	95% CI
<b>UNITED STATES</b>												
1	31.8	31.3 - 32.3	31.7	31.1 - 32.3	27.3	25.8 - 28.9	38.2	37.8 - 38.5	38.0	37.6 - 38.4	32.9	31.9 - 33.9
3	16.2	15.8 - 16.7	15.7	15.3 - 16.2	13.2	11.9 - 14.4	20.5	20.1 - 20.8	19.9	19.5 - 20.3	16.5	15.5 - 17.5
5	12.2	11.8 - 12.5	11.7	11.3 - 12.1	9.1	8.0 - 10.2	14.8	14.4 - 15.2	14.3	13.8 - 14.8	11.4	10.3 - 12.5
<b>NORTHEAST</b>												
<b>New England</b>												
Connecticut (SEER)												
1	35.4	31.0 - 39.8	36.6	31.8 - 41.4	30.5	18.1 - 42.9	42.8	40.0 - 45.6	42.7	39.7 - 45.8	43.9	35.0 - 52.9
3	17.4	13.9 - 20.9	18.3	14.4 - 22.3	17.3	6.9 - 27.7	22.3	19.6 - 25.1	22.7	19.6 - 25.8	20.4	12.2 - 28.7
5	12.4	9.2 - 15.5	12.8	9.4 - 16.2	13.5	3.4 - 23.5	14.5	11.4 - 17.7	14.9	11.4 - 18.5	16.1	7.7 - 24.4
Massachusetts (NPCR)												
1	36.4	33.3 - 39.4	35.3	32.0 - 38.7	34.2	23.3 - 45.0	43.0	40.9 - 45.0	41.7	39.5 - 44.0	41.8	33.1 - 50.5
3	17.9	15.4 - 20.3	16.1	13.5 - 18.7	16.8	8.2 - 25.3	24.2	22.1 - 26.4	21.8	19.5 - 24.1	27.5	18.2 - 36.8
5	14.0	11.7 - 16.4	13.1	10.6 - 15.5	10.3	3.4 - 17.2	15.6	13.0 - 18.2	13.6	10.9 - 16.4	20.3	13.0 - 27.6
New Hampshire (NPCR)												
1	32.4	24.9 - 39.8	29.6	21.9 - 37.3	-	-	34.9	29.6 - 40.2	35.5	30.1 - 41.0	-	-
3	16.0	10.1 - 21.8	14.5	8.7 - 20.4	-	-	15.7	11.2 - 20.3	16.2	11.4 - 21.0	-	-
5	12.2	6.9 - 17.5	10.9	5.7 - 16.1	-	-	12.5	8.6 - 16.4	12.4	8.3 - 16.4	-	-
Rhode Island (NPCR)												
1	30.3	23.6 - 37.0	29.6	23.1 - 36.2	40.7	12.4 - 69.0	36.1	30.9 - 41.2	34.9	29.7 - 40.0	51.6	34.0 - 69.3
3	16.9	11.3 - 22.5	16.4	10.9 - 21.9	20.6	0.0 - 42.9	16.8	12.3 - 21.3	14.4	10.2 - 18.7	28.5	10.6 - 46.4
5	12.8	7.7 - 17.8	11.7	6.8 - 16.6	20.6	0.0 - 42.9	10.7	6.8 - 14.7	9.9	6.1 - 13.6	14.3	0.0 - 31.3
<b>Mid Atlantic</b>												
New Jersey (NPCR/SEER)												
1	33.6	31.1 - 36.1	32.7	29.9 - 35.5	29.9	23.3 - 36.6	41.1	39.3 - 43.0	42.5	40.5 - 44.6	33.3	28.2 - 38.5
3	17.9	15.8 - 20.0	17.6	15.2 - 20.0	10.3	6.3 - 14.3	20.2	18.5 - 22.0	20.8	18.8 - 22.8	15.0	10.1 - 19.9
5	12.6	10.7 - 14.4	12.3	10.2 - 14.4	6.9	3.8 - 10.0	14.8	12.8 - 16.8	15.4	13.1 - 17.6	8.8	4.2 - 13.4
New York (NPCR)												
1	36.5	34.9 - 38.2	35.3	33.3 - 37.2	32.1	27.8 - 36.4	43.7	42.6 - 44.8	42.4	41.0 - 43.7	40.3	37.5 - 43.1
3	20.8	19.4 - 22.2	19.0	17.3 - 20.6	17.5	13.9 - 21.0	25.9	24.8 - 27.1	23.8	22.4 - 25.1	23.2	20.4 - 26.0
5	16.8	15.5 - 18.2	14.6	13.1 - 16.2	13.1	9.9 - 16.4	20.4	19.1 - 21.7	18.2	16.6 - 19.8	16.5	13.5 - 19.5
Pennsylvania (NPCR)												
1	32.1	29.9 - 34.2	32.7	30.2 - 35.1	29.4	23.7 - 35.1	39.8	38.3 - 41.3	39.5	37.8 - 41.2	39.0	34.6 - 43.4
3	17.0	15.2 - 18.7	17.0	14.9 - 19.0	13.3	9.0 - 17.6	20.1	18.7 - 21.6	20.0	18.4 - 21.7	14.3	11.2 - 17.5
5	12.3	10.7 - 13.9	12.2	10.4 - 14.0	7.9	4.8 - 11.1	15.1	13.5 - 16.8	14.7	12.8 - 16.5	13.4	10.2 - 16.5
<b>SOUTH</b>												
<b>South Atlantic</b>												
Delaware (NPCR)												
1	35.2	26.4 - 44.0	35.5	26.0 - 45.0	38.0	15.0 - 61.0	38.7	32.5 - 44.8	40.5	33.6 - 47.4	41.2	30.1 - 52.2
3	19.6	12.3 - 26.8	20.8	12.8 - 28.7	13.5	0.0 - 28.5	23.1	16.9 - 29.2	21.9	15.2 - 28.7	30.6	19.4 - 41.8
5	12.1	5.8 - 18.3	13.3	6.3 - 20.3	7.6	0.0 - 18.9	14.5	8.0 - 21.1	13.5	7.1 - 19.9	16.8	3.0 - 30.5
Florida (NPCR)												
1	33.8	32.0 - 35.6	34.6	32.6 - 36.6	26.2	20.4 - 32.0	41.3	40.1 - 42.5	42.1	40.7 - 43.5	33.1	29.4 - 36.7
3	18.5	16.9 - 20.0	18.4	16.7 - 20.1	17.3	12.0 - 22.6	24.8	23.5 - 26.0	25.1	23.7 - 26.5	18.9	15.5 - 22.3
5	14.8	13.3 - 16.2	14.5	12.9 - 16.1	14.3	9.0 - 19.6	20.9	19.3 - 22.4	20.8	19.1 - 22.6	17.4	13.7 - 21.1
Georgia (NPCR/SEER)												
1	25.6	22.5 - 28.8	25.7	21.9 - 29.5	23.7	17.5 - 29.9	35.0	32.9 - 37.1	36.1	33.6 - 38.5	31.6	27.2 - 36.0
3	11.4	9.1 - 13.7	11.7	8.9 - 14.5	8.9	4.8 - 12.9	17.7	15.8 - 19.7	18.5	16.1 - 20.8	15.6	11.5 - 19.8
5	7.6	5.6 - 9.6	8.2	5.7 - 10.6	4.5	1.7 - 7.2	12.5	10.4 - 14.6	13.3	10.8 - 15.7	10.9	6.3 - 15.4
Maryland (NPCR)												
1	26.9	23.4 - 30.4	28.8	24.3 - 33.4	22.1	16.1 - 28.2	34.5	31.9 - 37.1	35.5	32.1 - 38.8	29.7	24.9 - 34.5
3	13.7	10.9 - 16.5	12.6	9.3 - 15.9	13.7	8.5 - 18.8	16.9	14.5 - 19.4	17.0	14.0 - 19.9	12.4	8.5 - 16.2
5	10.7	8.1 - 13.3	9.7	6.7 - 12.7	10.8	6.1 - 15.5	13.4	10.8 - 16.0	13.5	10.6 - 16.5	8.9	5.0 - 12.7
North Carolina (NPCR)												
1	25.0	22.2 - 27.8	26.8	23.4 - 30.1	16.8	11.7 - 21.8	35.4	33.4 - 37.4	36.9	34.5 - 39.2	28.6	23.9 - 33.3
3	13.8	11.5 - 16.1	14.3	11.6 - 17.0	8.8	5.2 - 12.3	17.4	15.4 - 19.3	18.9	16.6 - 21.2	12.0	7.9 - 16.0
5	10.2	8.1 - 12.4	10.7	8.2 - 13.2	5.7	2.8 - 8.6	12.0	9.9 - 14.1	13.3	10.8 - 15.9	5.9	2.5 - 9.3
South Carolina (NPCR)												
1	27.6	23.6 - 31.6	28.8	24.2 - 33.5	29.9	20.8 - 39.0	30.1	27.4 - 32.9	31.7	28.4 - 35.0	23.4	17.9 - 28.8
3	14.5	11.2 - 17.7	15.4	11.6 - 19.2	16.0	8.1 - 23.8	13.3	10.7 - 15.9	15.7	12.5 - 18.8	6.8	3.4 - 10.3
5	10.0	7.2 - 12.7	11.6	8.2 - 15.1	6.7	2.2 - 11.1	10.4	7.7 - 13.1	11.9	8.5 - 15.2	6.5	2.5 - 10.4
West Virginia (NPCR)												
1	23.5	17.9 - 29.1	23.8	18.1 - 29.5	-	-	30.1	26.0 - 34.3	30.2	25.8 - 34.5	31.7	12.8 - 50.7
3	9.1	5.4 - 12.9	9.6	5.7 - 13.5	-	-	16.3	12.2 - 20.3	15.9	11.8 - 20.0	8.7	0.0 - 20.8
5	6.3	3.1 - 9.5	6.6	3.3 - 10.0	-	-	9.2	5.4 - 13.1	7.9	4.5 - 11.4	9.0	0.0 - 21.3
<b>East South Central</b>												
Alabama (NPCR)												
1	24.8	21.0 - 28.6	25.0	20.7 - 29.4	24.3	15.6 - 33.0	31.4	28.7 - 34.1	32.5	29.3 - 35.7	29.3	23.5 - 35.2
3	11.5	8.6 - 14.4	10.6	7.5 - 13.7	12.8	6.1 - 19.4	16.5	13.9 - 19.0	18.9	15.9 - 21.8	11.9	7.0 - 16.8
5	8.3	5.6 - 10.9	7.3	4.5 - 10.0	7.8	3.3 - 12.3	9.8	7.3 - 12.3	11.4	8.2 - 14.6	4.5	1.4 - 7.7
Kentucky (NPCR/SEER)												
1	30.6	26.3 - 34.9	30.4	25.9 - 34.9	35.2	20.7 - 49.6	32.5	29.8 - 35.2	32.6	29.8 - 35.5	36.6	27.7 - 45.5
3	13.7	10.5 - 17.0	13.9	10.5 - 17.3	14.2	3.6 - 24.8	18.4	15.8 - 21.1	18.3	15.6 - 21.1	15.6	7.1 - 24.2
5	10.3	7.4 - 13.2	10.3	7.3 - 13.3	11.9	1.8 - 21.9	11.2	8.5 - 14.0	11.6	8.6 - 14.5	9.8	1.8 - 17.8
Mississippi (NPCR)												
1	24.6	17.2 - 32.0	28.2	19.9 - 36.5	18.2	4.5 - 31.9	31.2	27.8 - 34.6	32.5	28.4 - 36.6	25.7	19.4 - 32.1
3	13.8	7.8 - 19.9	16.9	9.7 - 24.1	3.7	0.0 - 9.3	16.1	12.9 - 19.2	17.3	13.5 - 21.0	16.8	10.5 - 23.1
5	7.1	2.6 - 11.6	8.0	2.8 - 13.2	3.7	0.0 - 9.3	11.3	8.0 - 14.6	13.5	9.6 - 17.4	8.6	3.6 - 13.5
Tennessee (NPCR)												
1	26.9	20.7 - 33.2	28.0	21.4 - 34.6	23.2	6.5 - 40.0	35.1	32.5 - 37.7	35.0	32.1 - 37.8	32.3	25.9 - 38.8
3	11.8	7.8 - 15.9	14.0	9.3 - 18.6	4.8	0.0 - 12.1	17.0	14.6 - 19.4	16.2	13.6 - 18.8	18.3	12.2 - 24.4
5	8.2	4.6 - 11.7	10.0	5.9 - 14.1	0.0	-	11.5	9.0 - 13.9	10.7	8.2 - 13.2	12.0	5.9 - 18.1
<b>West South Central</b>												
Louisiana (NPCR/SEER)												
1	26.4	23.1 - 29.8	29.5	25.3 - 33.6	21.7	15.6 - 27.7	32.6	30.1 - 35.1	34.9	31.7 - 38.1	27.8	23.4 - 32.3
3	11.5	9.1 - 13.9	15.0	11.7 - 18.2	6.2	3.0 - 9.4	15.7	13.4 - 18.0	18.3	15.3 - 21.3	10.7	7.1 - 14.3
5	9.1	6.8 - 11.4	11.9	8.9 - 15.0	5.0	2.1 - 7.9	9.3	7.1 - 11.6	11.1	8.1 - 14.0	6.8	3.4 - 10.2



Years	2001-2003						2004-2009						
	All races		White		Black		All races		White		Black		
	NS	95% CI	NS	95% CI	NS	95% CI	NS	95% CI	NS	95% CI	NS	95% CI	
Oklahoma (NPCR)	1	26.3	22.1 - 30.6	27.4	22.4 - 32.3	27.7	13.5 - 42.0	31.5	28.7 - 34.3	32.6	29.3 - 35.8	36.1	24.7 - 47.6
	3	11.9	8.7 - 15.1	11.3	7.6 - 15.0	18.2	5.8 - 30.5	16.2	13.6 - 18.9	15.7	12.7 - 18.6	23.3	12.9 - 33.7
	5	8.1	5.4 - 10.8	6.9	4.0 - 9.8	13.2	1.8 - 24.5	10.9	8.0 - 13.9	11.1	8.1 - 14.2	23.7	12.6 - 34.8
Texas (NPCR)	1	33.2	31.6 - 34.8	33.8	32.0 - 35.6	28.8	23.3 - 34.4	37.0	35.9 - 38.0	37.3	36.1 - 38.5	29.5	26.4 - 32.7
	3	16.4	15.0 - 17.7	16.3	14.9 - 17.7	12.7	8.7 - 16.7	19.7	18.7 - 20.8	19.8	18.7 - 21.0	13.1	10.2 - 16.0
	5	12.0	10.9 - 13.2	11.9	10.6 - 13.2	10.0	6.0 - 14.1	14.1	12.9 - 15.3	14.3	12.9 - 15.6	8.0	5.8 - 10.3
<b>MIDWEST</b>													
<b>East North Central</b>													
Michigan (NPCR)	1	28.2	25.7 - 30.6	29.5	26.7 - 32.3	24.5	18.4 - 30.6	34.3	32.6 - 36.1	35.6	33.6 - 37.7	27.6	23.5 - 31.6
	3	15.6	13.6 - 17.6	15.9	13.6 - 18.2	14.3	9.3 - 19.4	19.2	17.5 - 20.9	19.8	17.8 - 21.8	16.7	12.8 - 20.6
	5	11.0	9.2 - 12.8	11.6	9.5 - 13.7	7.9	4.3 - 11.5	15.2	13.3 - 17.1	16.4	14.2 - 18.6	6.1	4.1 - 8.0
Ohio (NPCR)	1	27.0	24.5 - 29.5	28.4	25.5 - 31.2	24.4	18.4 - 30.5	33.1	31.3 - 34.8	33.5	31.6 - 35.5	29.9	25.4 - 34.4
	3	12.7	10.8 - 14.7	14.1	11.8 - 16.4	7.8	4.3 - 11.2	17.2	15.6 - 18.9	17.1	15.3 - 19.0	15.8	11.9 - 19.6
	5	9.1	7.4 - 10.8	10.3	8.2 - 12.3	4.7	2.1 - 7.3	12.7	10.8 - 14.5	12.2	10.2 - 14.3	13.9	10.0 - 17.7
Wisconsin (NPCR)	1	34.4	30.8 - 38.1	34.9	31.1 - 38.8	38.2	24.1 - 52.4	40.5	37.9 - 43.1	41.2	38.4 - 44.1	30.7	21.7 - 39.7
	3	16.8	13.8 - 19.9	16.8	13.5 - 20.0	22.8	10.6 - 35.0	20.4	17.8 - 22.9	20.9	18.1 - 23.6	13.4	7.1 - 19.7
	5	13.9	10.9 - 16.9	14.0	10.8 - 17.2	13.9	4.0 - 23.9	11.5	9.0 - 14.1	12.0	9.2 - 14.7	10.1	1.6 - 18.6
<b>West North Central</b>													
Iowa (SEER)	1	27.1	22.0 - 32.2	27.5	22.5 - 32.4	-	-	38.7	35.2 - 42.2	39.7	36.0 - 43.3	43.5	25.5 - 61.6
	3	14.6	10.6 - 18.7	15.5	11.5 - 19.5	-	-	19.4	16.0 - 22.9	20.7	17.1 - 24.4	19.8	2.2 - 37.3
	5	12.0	8.3 - 15.7	12.6	8.9 - 16.3	-	-	16.5	12.9 - 20.1	17.7	13.9 - 21.5	19.9	2.2 - 37.5
Nebraska (NPCR)	1	32.9	27.0 - 38.8	34.3	28.0 - 40.6	37.0	10.9 - 63.1	40.3	36.2 - 44.3	41.4	37.1 - 45.8	38.8	24.0 - 53.5
	3	17.3	12.6 - 22.0	17.5	12.5 - 22.4	28.5	4.2 - 52.9	19.9	16.0 - 23.8	20.6	16.5 - 24.7	18.5	5.3 - 31.7
	5	12.7	8.5 - 16.9	12.6	8.1 - 17.0	23.7	0.0 - 48.2	14.9	11.3 - 18.5	15.3	11.5 - 19.1	19.0	5.5 - 32.5
<b>WEST</b>													
<b>Mountain</b>													
Colorado (NPCR)	1	29.8	25.7 - 33.8	28.7	24.3 - 33.1	41.2	24.5 - 57.9	37.5	34.7 - 40.4	36.7	33.7 - 39.7	27.8	16.8 - 38.7
	3	13.9	10.9 - 17.0	13.8	10.5 - 17.1	9.8	0.1 - 19.5	20.1	17.5 - 22.8	19.6	16.8 - 22.4	10.9	1.5 - 20.3
	5	11.5	8.7 - 14.3	11.3	8.3 - 14.4	6.9	0.0 - 15.0	16.0	13.2 - 18.9	15.6	12.6 - 18.6	11.0	1.5 - 20.5
Idaho (NPCR)	1	31.5	22.5 - 40.5	32.1	22.8 - 41.4	-	-	36.8	31.5 - 42.2	37.6	32.0 - 43.1	-	-
	3	18.4	11.2 - 25.6	18.4	10.9 - 25.9	-	-	19.4	14.2 - 24.6	20.0	14.6 - 25.4	-	-
	5	15.4	8.1 - 22.6	15.2	7.7 - 22.7	-	-	11.5	6.5 - 16.4	11.8	6.6 - 17.1	-	-
Montana (NPCR)	1	29.1	19.1 - 39.1	28.6	18.1 - 39.1	-	-	35.9	29.6 - 42.2	38.2	31.3 - 45.1	-	-
	3	14.7	7.3 - 22.1	15.2	7.5 - 22.8	-	-	15.4	9.7 - 21.0	16.8	10.6 - 23.0	-	-
	5	13.9	5.7 - 22.1	13.9	5.2 - 22.7	-	-	11.1	5.5 - 16.6	11.8	5.9 - 17.8	-	-
New Mexico (SEER)	1	27.2	22.4 - 32.0	25.9	20.9 - 31.0	-	-	32.0	28.6 - 35.3	31.5	27.9 - 35.1	37.2	13.1 - 61.4
	3	11.2	7.7 - 14.7	11.0	7.3 - 14.6	-	-	13.9	11.1 - 16.8	13.4	10.3 - 16.4	18.9	0.0 - 41.2
	5	7.0	4.3 - 9.7	6.9	4.0 - 9.7	-	-	9.7	7.1 - 12.4	9.9	7.0 - 12.9	-	-
Utah (SEER)	1	28.8	21.6 - 36.0	29.4	22.0 - 36.9	-	-	38.7	33.7 - 43.7	40.4	35.0 - 45.7	27.4	3.6 - 51.2
	3	13.7	8.3 - 19.1	13.2	7.7 - 18.6	-	-	18.9	14.3 - 23.6	20.7	15.6 - 25.7	0.2	0.0 - 0.5
	5	11.4	6.5 - 16.3	11.7	6.5 - 17.0	-	-	9.8	5.9 - 13.7	10.7	6.4 - 15.0	-	-
Wyoming (NPCR)	1	30.4	16.3 - 44.4	32.8	17.8 - 47.7	-	-	31.8	24.2 - 39.5	32.3	24.6 - 40.0	-	-
	3	5.4	0.0 - 12.0	5.9	0.0 - 12.9	-	-	16.0	9.9 - 22.1	16.3	10.1 - 22.5	-	-
	5	2.7	0.0 - 7.0	3.0	0.0 - 7.6	-	-	8.1	2.2 - 13.9	8.1	2.3 - 14.0	-	-
<b>Pacific</b>													
Alaska (NPCR)	1	33.3	23.4 - 43.2	34.3	22.6 - 46.1	-	-	38.5	31.6 - 45.4	37.1	28.2 - 46.0	31.5	10.0 - 52.9
	3	11.7	6.2 - 17.2	14.7	6.0 - 23.4	-	-	25.9	18.9 - 32.8	21.4	14.3 - 28.5	8.1	0.0 - 20.0
	5	9.0	3.9 - 14.0	9.8	2.6 - 17.0	-	-	16.6	9.4 - 23.7	13.1	6.9 - 19.4	-	-
California (NPCR/SEER)	1	32.9	31.7 - 34.1	31.2	29.8 - 32.7	25.6	21.4 - 29.8	39.5	38.7 - 40.3	37.2	36.2 - 38.2	31.5	28.4 - 34.5
	3	16.3	15.3 - 17.3	14.4	13.3 - 15.6	10.0	7.4 - 12.6	21.1	20.3 - 21.9	18.7	17.7 - 19.6	16.1	13.2 - 18.9
	5	11.4	10.6 - 12.3	10.1	9.1 - 11.1	7.2	5.1 - 9.3	14.8	13.8 - 15.8	12.8	11.7 - 13.9	11.7	8.5 - 14.9
Hawaii (SEER)	1	34.8	29.8 - 39.8	37.3	23.9 - 50.7	-	-	40.5	36.9 - 44.1	34.3	26.9 - 41.7	53.6	25.1 - 82.2
	3	18.2	14.2 - 22.3	21.2	9.7 - 32.7	-	-	23.1	19.4 - 26.8	23.0	15.9 - 30.1	21.4	0.0 - 44.1
	5	15.2	11.3 - 19.1	19.8	8.4 - 31.1	-	-	13.2	8.8 - 17.6	16.8	9.0 - 24.7	21.8	0.0 - 44.9
Oregon (NPCR)	1	26.8	22.6 - 31.1	25.5	20.9 - 30.1	-	-	34.7	31.9 - 37.5	33.2	30.2 - 36.2	42.1	26.2 - 57.9
	3	10.2	7.2 - 13.2	8.6	5.7 - 11.6	-	-	15.7	13.1 - 18.2	14.1	11.3 - 16.8	24.3	8.8 - 39.8
	5	6.9	4.3 - 9.5	5.9	3.3 - 8.5	-	-	11.2	8.7 - 13.8	10.1	7.4 - 12.8	6.3	0.0 - 15.3
Washington (NPCR)	1	32.2	29.0 - 35.4	31.2	27.6 - 34.9	35.8	19.9 - 51.7	40.3	38.1 - 42.5	38.4	35.9 - 40.9	49.0	39.4 - 58.7
	3	15.3	12.8 - 17.8	13.9	11.2 - 16.7	21.1	7.4 - 34.8	22.1	20.0 - 24.2	20.4	18.0 - 22.7	21.6	12.5 - 30.8
	5	11.8	9.5 - 14.1	10.7	8.1 - 13.2	12.3	1.6 - 23.1	14.7	12.4 - 17.0	13.9	11.3 - 16.4	8.1	4.6 - 11.7

SEER Summary Stage	2001-2003						2004-2009						
	All races		White		Black		All races		White		Black		
	NS (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI	
<b>UNITED STATES</b>													
All stages	12.2	11.8 - 12.5	11.7	11.3 - 12.1	9.1	8.0 - 10.2	14.8	14.4 - 15.2	14.3	13.8 - 14.8	11.4	10.3 - 12.5	
Localized	22.9	22.1 - 23.8	22.4	21.4 - 23.4	15.8	13.3 - 18.2	25.7	24.9 - 26.5	24.8	23.9 - 25.7	20.8	18.4 - 23.3	
Regional	8.3	7.6 - 9.0	7.6	6.8 - 8.4	8.3	6.3 - 10.4	9.5	8.8 - 10.2	9.2	8.4 - 9.9	7.1	5.4 - 8.9	
Distant	2.8	2.4 - 3.3	2.4	2.0 - 2.9	2.5	1.2 - 3.8	3.5	3.0 - 4.0	2.9	2.3 - 3.4	3.8	2.6 - 5.1	
Unknown	8.2	7.6 - 8.9	7.9	7.2 - 8.7	7.0	5.3 - 8.8	8.9	8.2 - 9.6	9.0	8.1 - 9.8	6.2	4.6 - 7.8	
<b>NORTHEAST</b>													
<b>New England</b>													
Connecticut (SEER)	All stages	12.4	9.2 - 15.5	12.8	9.4 - 16.2	13.5	3.4 - 23.5	14.5	11.4 - 17.7	14.9	11.4 - 18.5	16.1	7.7 - 24.4
	Localized	23.6	17.0 - 30.2	25.3	18.2 - 32.4	8.9	0.0 - 22.0	23.7	17.2 - 30.3	23.6	16.6 - 30.6	22.4	6.2 - 38.6
	Regional	7.7	3.4 - 11.9	4.3	1.3 - 7.2	34.3	8.8 - 59.8	8.1	4.7 - 11.5	8.8	4.8 - 12.8	-	-
	Distant	1.6	0.0 - 3.8	0.0	0.0 - 0.0	-	-	5.8	2.6 - 9.0	4.1	0.6 - 7.6	15.1	0.5 - 29.7
	Unknown	8.6	3.9 - 13.2	9.6	4.5 - 14.8	0.0	-	9.5	6.0 - 13.1	9.3	5.7 - 13.0	-	-
Massachusetts (NPCR)	All stages	14.0	11.7 - 16.4	13.1	10.6 - 15.5	10.3	3.4 - 17.2	15.6	13.0 - 18.2	13.6	10.9 - 16.4	20.3	13.0 - 27.6
	Localized	31.0	25.4 - 36.6	28.5	22.9 - 34.0	22.2	3.7 - 40.7	28.1	23.0 - 33.2	26.5	21.1 - 31.9	14.6	0.0 - 32.5
	Regional	8.0	4.6 - 11.4	7.9	4.6 - 11.3	9.9	0.0 - 21.0	10.5	6.7 - 14.4	9.5	5.6 - 13.4	9.3	0.0 - 20.2
	Distant	2.6	0.5 - 4.6	2.2	0.4 - 4.0	0.0	-	4.7	2.4 - 7.0	2.2	0.0 - 4.5	-	-
	Unknown	3.8	1.4 - 6.1	2.8	1.1 - 4.6	0.0	-	3.9	1.8 - 6.0	1.6	0.5 - 2.8	10.0	0.0 - 20.9
New Hampshire (NPCR)	All stages	12.2	6.9 - 17.5	10.9	5.7 - 16.1	-	-	12.5	8.6 - 16.4	12.4	8.3 - 16.4	-	-
	Localized	32.9	16.2 - 49.5	33.7	15.8 - 51.6	-	-	24.2	15.9 - 32.4	25.6	17.2 - 34.1	-	-
	Regional	10.1	0.2 - 20.0	4.3	0.0 - 10.8	-	-	10.0	2.6 - 17.3	8.7	1.6 - 15.9	-	-
	Distant	0.0	-	0.0	-	-	-	-	-	-	-	-	-
	Unknown	2.3	0.0 - 6.1	2.5	0.0 - 6.5	-	-	3.5	0.0 - 8.5	4.0	0.0 - 9.6	-	-
Rhode Island (NPCR)	All stages	12.8	7.7 - 17.8	11.7	6.8 - 16.6	20.6	0.0 - 42.9	10.7	6.8 - 14.7	9.9	6.1 - 13.6	14.3	0.0 - 31.3
	Localized	22.2	10.0 - 34.5	19.8	7.5 - 32.1	-	-	-	-	-	-	-	-
	Regional	11.3	2.4 - 20.3	12.5	2.7 - 22.4	-	-	-	-	-	-	-	-
	Distant	8.5	0.0 - 18.2	5.7	0.0 - 14.2	-	-	-	-	-	-	-	-
	Unknown	4.5	0.0 - 10.2	4.6	0.0 - 10.4	-	-	-	-	-	-	-	-
<b>Mid Atlantic</b>													
New Jersey (NPCR/SEER)	All stages	12.6	10.7 - 14.4	12.3	10.2 - 14.4	6.9	3.8 - 10.0	14.8	12.8 - 16.8	15.4	13.1 - 17.6	8.8	4.2 - 13.4
	Localized	23.4	19.3 - 27.4	23.0	18.3 - 27.7	21.7	11.2 - 32.2	23.9	20.1 - 27.6	25.0	20.8 - 29.2	16.5	7.1 - 25.9
	Regional	7.9	4.7 - 11.1	9.0	5.2 - 12.8	2.5	0.0 - 6.5	10.0	6.5 - 13.5	9.3	5.6 - 12.9	11.2	3.3 - 19.0
	Distant	0.9	0.0 - 1.8	1.2	0.0 - 2.5	0.0	-	3.4	1.6 - 5.2	4.1	2.0 - 6.2	2.2	0.0 - 5.0
	Unknown	12.0	8.6 - 15.3	10.2	7.0 - 13.5	13.3	3.5 - 23.0	11.1	7.7 - 14.5	12.0	7.9 - 16.0	-	-
New York (NPCR)	All stages	16.8	15.5 - 18.2	14.6	13.1 - 16.2	13.1	9.9 - 16.4	20.4	19.1 - 21.7	18.2	16.6 - 19.8	16.5	13.5 - 19.5
	Localized	32.0	28.8 - 35.2	30.3	26.5 - 34.1	18.2	11.3 - 25.2	34.0	31.4 - 36.7	30.2	27.0 - 33.4	30.2	23.9 - 36.4
	Regional	14.9	12.2 - 17.6	11.0	8.1 - 13.8	18.5	11.7 - 25.3	13.9	11.6 - 16.2	13.1	10.3 - 15.9	12.2	8.0 - 16.5
	Distant	5.9	4.1 - 7.8	4.0	2.2 - 5.8	3.3	1.3 - 5.3	5.3	3.7 - 6.8	4.1	2.6 - 5.6	9.1	5.3 - 12.9
	Unknown	10.5	8.6 - 12.4	8.7	6.5 - 10.9	9.0	4.3 - 13.7	13.5	11.1 - 16.0	13.6	10.8 - 16.5	4.1	1.7 - 6.5
Pennsylvania (NPCR)	All stages	12.3	10.7 - 13.9	12.2	10.4 - 14.0	7.9	4.8 - 11.1	15.1	13.5 - 16.8	14.7	12.8 - 16.5	13.4	10.2 - 16.5
	Localized	23.5	19.9 - 27.0	23.6	19.6 - 27.5	9.9	5.2 - 14.5	25.4	22.1 - 28.7	25.6	21.9 - 29.3	23.4	16.2 - 30.6
	Regional	7.8	5.3 - 10.3	7.2	4.5 - 9.8	8.1	2.2 - 14.1	8.7	6.4 - 11.1	9.4	6.6 - 12.2	10.6	5.4 - 15.7
	Distant	1.5	0.3 - 2.6	1.3	0.0 - 2.6	0.0	0.0 - 0.0	5.4	3.5 - 7.2	4.5	2.7 - 6.4	5.1	1.1 - 9.1
	Unknown	9.2	6.2 - 12.3	6.7	3.8 - 9.6	8.7	2.9 - 14.5	8.0	5.2 - 10.9	5.9	3.2 - 8.6	11.5	2.8 - 20.2
<b>SOUTH</b>													
<b>South Atlantic</b>													
Delaware (NPCR)	All stages	12.1	5.8 - 18.3	13.3	6.3 - 20.3	7.6	0.0 - 18.9	14.5	8.0 - 21.1	13.5	7.1 - 19.9	16.8	3.0 - 30.5
	Localized	25.5	11.1 - 39.8	27.8	11.4 - 44.2	-	-	24.7	13.0 - 36.4	17.5	9.6 - 25.3	40.5	13.6 - 67.5
	Regional	10.2	0.0 - 22.2	15.6	0.0 - 33.5	-	-	0.0	0.0 - 0.1	9.1	0.0 - 19.0	0.7	0.0 - 2.3
	Distant	0.0	-	0.0	-	-	-	-	-	-	-	-	-
	Unknown	0.0	-	0.0	-	-	-	5.9	0.0 - 14.5	8.4	0.0 - 20.5	-	-
Florida (NPCR)	All stages	14.8	13.3 - 16.2	14.5	12.9 - 16.1	14.3	9.0 - 19.6	20.9	19.3 - 22.4	20.8	19.1 - 22.6	17.4	13.7 - 21.1
	Localized	26.4	23.0 - 29.7	26.8	23.2 - 30.4	14.8	6.6 - 22.9	32.8	29.9 - 35.6	32.7	29.7 - 35.7	30.3	22.3 - 38.3
	Regional	10.7	7.9 - 13.5	9.4	6.6 - 12.2	15.8	6.7 - 24.8	14.8	11.8 - 17.7	14.5	11.3 - 17.8	9.5	4.9 - 14.1
	Distant	5.5	3.4 - 7.5	4.7	2.7 - 6.7	6.9	0.7 - 13.1	8.1	5.8 - 10.4	7.0	4.6 - 9.3	9.7	3.3 - 16.1
	Unknown	12.5	10.1 - 15.0	12.4	9.7 - 15.0	14.4	6.5 - 22.3	16.3	13.3 - 19.2	16.4	13.0 - 19.7	11.2	6.0 - 16.5
Georgia (NPCR/SEER)	All stages	7.6	5.6 - 9.6	8.2	5.7 - 10.6	4.5	1.7 - 7.2	12.5	10.4 - 14.6	13.3	10.8 - 15.7	10.9	6.3 - 15.4
	Localized	16.5	11.9 - 21.2	19.4	13.7 - 25.1	6.9	1.5 - 12.2	22.7	18.6 - 26.9	22.7	18.0 - 27.3	24.4	15.3 - 33.6
	Regional	2.4	0.0 - 4.9	2.6	0.0 - 5.9	2.0	0.0 - 5.2	6.4	3.7 - 9.2	8.3	4.8 - 11.8	4.4	1.7 - 7.0
	Distant	0.0	0.0 - 0.0	0.0	0.0 - 0.0	0.1	0.0 - 0.3	4.1	1.8 - 6.4	5.0	2.1 - 7.8	3.3	0.0 - 6.8
	Unknown	5.5	2.5 - 8.5	3.2	1.0 - 5.3	9.2	0.5 - 17.8	8.4	4.6 - 12.2	8.0	4.1 - 11.9	8.7	0.0 - 18.1
Maryland (NPCR)	All stages	10.7	8.1 - 13.3	9.7	6.7 - 12.7	10.8	6.1 - 15.5	13.4	10.8 - 16.0	13.5	10.6 - 16.5	8.9	5.0 - 12.7
	Localized	-	-	-	-	-	-	-	-	-	-	-	-
	Regional	-	-	-	-	-	-	-	-	-	-	-	-
	Distant	-	-	-	-	-	-	-	-	-	-	-	-
	Unknown	-	-	-	-	-	-	-	-	-	-	-	-

		2001-2003						2004-2009					
		All races		White		Black		All races		White		Black	
SEER	Summary Stage	NS (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI
North Carolina (NPCR)	All stages	10.2	8.1 - 12.4	10.7	8.2 - 13.2	5.7	2.8 - 8.6	12.0	9.9 - 14.1	13.3	10.8 - 15.9	5.9	2.5 - 9.3
	Localized	17.5	13.1 - 21.8	17.6	12.7 - 22.5	9.7	3.3 - 16.2	21.7	17.2 - 26.2	25.3	19.9 - 30.6	6.4	3.0 - 9.9
	Regional	6.7	3.2 - 10.1	5.1	1.8 - 8.4	11.9	2.6 - 21.1	6.2	3.5 - 8.9	6.0	3.0 - 9.0	3.2	0.0 - 7.3
	Distant	2.7	0.8 - 4.6	3.3	1.1 - 5.4	0.0	-	3.4	1.2 - 5.6	3.1	0.9 - 5.2	-	-
	Unknown	7.4	3.9 - 10.8	8.0	4.1 - 12.0	1.9	0.3 - 3.6	6.0	2.9 - 9.0	4.6	2.1 - 7.2	10.3	2.2 - 18.5
South Carolina (NPCR)	All stages	10.0	7.2 - 12.7	11.6	8.2 - 15.1	6.7	2.2 - 11.1	10.4	7.7 - 13.1	11.9	8.5 - 15.2	6.5	2.5 - 10.4
	Localized	18.2	12.7 - 23.7	20.0	13.4 - 26.5	12.7	1.3 - 24.2	20.8	15.4 - 26.2	24.5	18.2 - 30.9	13.5	5.1 - 21.9
	Regional	7.9	3.1 - 12.8	10.6	4.5 - 16.7	5.4	0.0 - 13.8	4.3	1.4 - 7.1	3.8	0.0 - 7.8	0.1	0.0 - 0.2
	Distant	0.0	-	0.0	-	0.0	-	3.5	0.1 - 6.8	5.2	0.3 - 10.1	-	-
	Unknown	4.8	1.9 - 7.8	4.2	1.0 - 7.4	7.6	0.0 - 15.5	6.0	2.8 - 9.2	5.3	0.4 - 10.2	6.0	0.0 - 13.4
West Virginia (NPCR)	All stages	6.3	3.1 - 9.5	6.6	3.3 - 10.0	-	-	9.2	5.4 - 13.1	7.9	4.5 - 11.4	9.0	0.0 - 21.3
	Localized	11.5	2.9 - 20.1	11.9	3.0 - 20.8	-	-	16.2	8.7 - 23.7	16.9	9.1 - 24.7	-	-
	Regional	15.6	3.6 - 27.6	16.1	3.8 - 28.3	-	-	15.2	6.0 - 24.5	15.2	5.9 - 24.5	-	-
	Distant	3.0	0.0 - 7.4	3.1	0.0 - 7.7	-	-	8.3	1.5 - 15.1	9.0	1.7 - 16.3	-	-
	Unknown	0.0	-	0.0	-	-	-	2.2	0.0 - 5.5	2.0	0.0 - 5.0	-	-
<b>East South Central</b>													
Alabama (NPCR)	All stages	8.3	5.6 - 10.9	7.3	4.5 - 10.0	7.8	3.3 - 12.3	9.8	7.3 - 12.3	11.4	8.2 - 14.6	4.5	1.4 - 7.7
	Localized	15.1	9.7 - 20.5	13.2	7.5 - 18.9	24.2	9.9 - 38.6	19.7	15.4 - 24.0	20.3	15.9 - 24.6	13.9	4.1 - 23.8
	Regional	5.3	1.3 - 9.2	5.5	1.0 - 10.0	4.3	0.0 - 11.0	3.4	1.2 - 5.6	5.5	2.6 - 8.5	0.1	0.0 - 0.3
	Distant	3.4	0.0 - 7.9	1.1	0.0 - 2.4	0.0	-	2.8	0.0 - 5.7	3.2	0.1 - 6.3	0.3	0.0 - 0.9
	Unknown	4.7	1.5 - 7.9	4.0	0.8 - 7.1	6.0	0.0 - 13.0	2.8	0.5 - 5.1	3.8	1.0 - 6.5	0.1	0.0 - 0.3
Kentucky (NPCR/SEER)	All stages	10.3	7.4 - 13.2	10.3	7.3 - 13.3	11.9	1.8 - 21.9	11.2	8.5 - 14.0	11.6	8.6 - 14.5	9.8	1.8 - 17.8
	Localized	21.9	15.7 - 28.2	21.8	15.4 - 28.2	24.2	2.8 - 45.6	18.8	13.7 - 24.0	20.0	15.0 - 25.1	16.5	1.6 - 31.4
	Regional	2.2	0.0 - 4.5	1.4	0.0 - 3.6	8.3	0.0 - 20.9	10.6	6.5 - 14.6	11.6	7.3 - 16.0	-	-
	Distant	0.0	0.0 - 0.0	0.0	0.0 - 0.0	-	-	2.1	0.3 - 3.9	1.8	0.0 - 4.3	6.4	0.0 - 14.1
	Unknown	6.2	3.3 - 9.2	7.0	3.8 - 10.2	-	-	4.4	1.5 - 7.3	2.9	0.5 - 5.4	-	-
Mississippi (NPCR)	All stages	7.1	2.6 - 11.6	8.0	2.8 - 13.2	3.7	0.0 - 9.3	11.3	8.0 - 14.6	13.5	9.6 - 17.4	8.6	3.6 - 13.5
	Localized	12.1	2.3 - 21.9	13.3	1.5 - 25.1	10.4	0.0 - 25.6	23.3	16.7 - 29.8	24.7	17.2 - 32.2	19.2	5.5 - 32.8
	Regional	12.2	0.2 - 24.2	11.8	0.0 - 25.5	-	-	5.1	1.0 - 9.2	3.7	0.0 - 8.0	4.8	0.0 - 10.8
	Distant	0.0	-	0.0	-	-	-	3.8	0.2 - 7.5	5.2	0.4 - 9.9	-	-
	Unknown	0.0	-	0.0	-	-	-	3.7	0.0 - 8.5	3.2	0.0 - 7.8	16.0	2.0 - 30.0
Tennessee (NPCR)	All stages	8.2	4.6 - 11.7	10.0	5.9 - 14.1	0.0	-	11.5	9.0 - 13.9	10.7	8.2 - 13.2	12.0	5.9 - 18.1
	Localized	14.6	7.8 - 21.3	19.0	9.0 - 29.0	-	-	20.4	15.8 - 25.0	18.6	13.9 - 23.4	24.2	12.9 - 35.5
	Regional	5.4	0.0 - 11.8	6.0	0.0 - 13.1	-	-	6.6	3.7 - 9.6	7.5	3.9 - 11.1	0.2	0.0 - 0.7
	Distant	3.5	0.0 - 8.8	4.3	0.0 - 10.8	-	-	0.0	0.0 - 0.1	0.0	0.0 - 0.1	5.8	0.0 - 12.5
	Unknown	3.3	0.0 - 8.4	4.0	0.0 - 10.0	-	-	6.2	2.7 - 9.8	3.9	0.5 - 7.3	0.3	0.0 - 1.0
<b>West South Central</b>													
Louisiana (NPCR/SEER)	All stages	9.1	6.8 - 11.4	11.9	8.9 - 15.0	5.0	2.1 - 7.9	9.3	7.1 - 11.6	11.1	8.1 - 14.0	6.8	3.4 - 10.2
	Localized	17.9	13.2 - 22.7	21.8	16.0 - 27.6	11.4	4.2 - 18.7	15.1	11.2 - 19.0	17.8	12.8 - 22.8	11.2	5.4 - 17.0
	Regional	4.1	1.3 - 7.0	4.9	1.2 - 8.5	1.9	0.0 - 4.9	6.2	3.4 - 8.9	8.4	4.8 - 12.0	2.5	0.0 - 5.3
	Distant	0.0	0.0 - 0.0	0.0	0.0 - 0.0	0.0	-	2.3	0.6 - 4.0	0.0	0.0 - 0.0	4.4	0.1 - 8.7
	Unknown	5.0	1.2 - 8.8	4.2	0.0 - 8.5	3.3	0.0 - 8.5	5.3	1.0 - 9.7	6.0	0.4 - 11.7	4.2	0.0 - 9.3
Oklahoma (NPCR)	All stages	8.1	5.4 - 10.8	6.9	4.0 - 9.8	13.2	1.8 - 24.5	10.9	8.0 - 13.9	11.1	8.1 - 14.2	23.7	12.6 - 34.8
	Localized	15.6	10.1 - 21.2	12.8	7.4 - 18.1	-	-	17.3	11.7 - 22.8	18.6	12.9 - 24.3	22.8	0.0 - 46.4
	Regional	3.8	0.0 - 8.2	2.5	0.0 - 6.4	-	-	3.5	0.6 - 6.5	5.0	1.3 - 8.8	8.7	0.0 - 21.1
	Distant	1.2	0.0 - 3.0	0.0	0.0 - 0.0	-	-	3.7	0.4 - 7.0	3.7	0.4 - 6.9	13.1	0.0 - 27.0
	Unknown	7.2	3.5 - 11.0	6.3	1.3 - 11.3	13.8	0.0 - 29.5	11.0	7.3 - 14.6	9.9	6.2 - 13.7	27.3	5.8 - 48.7
Texas (NPCR)	All stages	12.0	10.9 - 13.2	11.9	10.6 - 13.2	10.0	6.0 - 14.1	14.1	12.9 - 15.3	14.3	12.9 - 15.6	8.0	5.8 - 10.3
	Localized	19.5	17.0 - 22.0	19.0	16.3 - 21.7	16.3	9.3 - 23.3	22.6	20.3 - 24.9	22.2	19.7 - 24.7	15.1	10.0 - 20.1
	Regional	7.5	5.3 - 9.8	6.6	4.3 - 8.9	7.9	1.3 - 14.5	7.9	5.8 - 10.0	8.4	6.1 - 10.7	3.7	1.1 - 6.3
	Distant	3.7	2.2 - 5.2	3.7	2.1 - 5.4	2.3	0.2 - 4.3	3.0	1.9 - 4.2	3.1	1.8 - 4.3	4.4	1.4 - 7.4
	Unknown	11.4	9.4 - 13.4	11.0	8.9 - 13.1	8.0	2.0 - 14.0	12.2	10.0 - 14.4	12.6	10.2 - 15.0	10.2	6.4 - 13.9
<b>MIDWEST</b>													
<b>East North Central</b>													
Michigan (NPCR)	All stages	11.0	9.2 - 12.8	11.6	9.5 - 13.7	7.9	4.3 - 11.5	15.2	13.3 - 17.1	16.4	14.2 - 18.6	6.1	4.1 - 8.0
	Localized	23.9	19.3 - 28.4	24.5	19.4 - 29.5	14.2	6.2 - 22.1	26.7	22.2 - 31.2	28.3	23.4 - 33.2	13.5	9.3 - 17.8
	Regional	7.2	4.3 - 10.2	7.9	4.7 - 11.0	9.1	1.8 - 16.4	16.2	11.7 - 20.7	16.3	11.1 - 21.5	9.6	1.4 - 17.8
	Distant	1.6	0.3 - 2.8	1.7	0.3 - 3.1	3.1	0.0 - 6.9	5.7	3.5 - 7.9	5.4	3.0 - 7.7	2.5	0.0 - 5.6
	Unknown	6.1	3.8 - 8.5	4.7	2.7 - 6.7	6.9	0.6 - 13.3	7.9	5.7 - 10.1	8.9	6.2 - 11.5	4.0	0.1 - 7.9
Ohio (NPCR)	All stages	9.1	7.4 - 10.8	10.3	8.2 - 12.3	4.7	2.1 - 7.3	12.7	10.8 - 14.5	12.2	10.2 - 14.3	13.9	10.0 - 17.7
	Localized	17.9	13.8 - 22.0	18.8	14.1 - 23.5	15.0	5.6 - 24.3	28.9	24.6 - 33.1	29.0	24.2 - 33.7	28.2	19.6 - 36.7
	Regional	5.6	3.0 - 8.2	6.9	3.6 - 10.3	5.6	0.0 - 12.3	8.3	5.6 - 11.0	8.9	5.7 - 12.1	12.1	5.8 - 18.4
	Distant	1.7	0.4 - 3.1	1.9	0.3 - 3.4	0.0	-	3.3	1.2 - 5.3	2.9	1.1 - 4.8	5.3	0.0 - 10.7
	Unknown	6.5	4.1 - 8.9	8.2	5.5 - 10.9	3.0	0.0 - 6.5	2.9	1.3 - 4.5	2.3	0.8 - 3.7	2.0	0.3 - 3.8

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

		2001-2003						2004-2009					
		All races		White		Black		All races		White		Black	
SEER	Summary Stage	NS (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI
Wisconsin (NPCR)	All stages	13.9	10.9 - 16.9	14.0	10.8 - 17.2	13.9	4.0 - 23.9	11.5	9.0 - 14.1	12.0	9.2 - 14.7	10.1	1.6 - 18.6
	Localized	-	-	-	-	-	-	-	-	-	-	-	-
	Regional	-	-	-	-	-	-	-	-	-	-	-	-
	Distant	-	-	-	-	-	-	-	-	-	-	-	-
	Unknown	-	-	-	-	-	-	-	-	-	-	-	-
<b>West North Central</b>													
Iowa (SEER)	All stages	12.0	8.3 - 15.7	12.6	8.9 - 16.3	-	-	16.5	12.9 - 20.1	17.7	13.9 - 21.5	19.9	2.2 - 37.5
	Localized	31.9	23.8 - 40.0	32.8	24.3 - 41.3	-	-	38.7	30.9 - 46.5	40.4	32.6 - 48.2	-	-
	Regional	1.2	0.0 - 3.0	1.2	0.0 - 3.0	-	-	9.1	5.3 - 12.8	9.9	6.0 - 13.7	-	-
	Distant	1.8	0.0 - 4.9	2.0	0.0 - 5.3	-	-	1.3	0.0 - 3.2	-	-	-	-
	Unknown	1.8	0.0 - 4.6	1.9	0.0 - 5.0	-	-	2.7	0.0 - 5.9	2.7	0.0 - 6.0	-	-
Nebraska (NPCR)	All stages	12.7	8.5 - 16.9	12.6	8.1 - 17.0	23.7	0.0 - 48.2	14.9	11.3 - 18.5	15.3	11.5 - 19.1	19.0	5.5 - 32.5
	Localized	23.7	15.3 - 32.1	23.5	14.4 - 32.6	-	-	26.5	19.5 - 33.5	25.7	18.6 - 32.8	52.8	17.3 - 88.3
	Regional	12.5	3.4 - 21.6	14.4	3.9 - 24.8	-	-	12.2	7.5 - 16.9	14.1	7.0 - 21.1	15.5	0.0 - 32.8
	Distant	3.6	0.0 - 8.8	0.0	-	-	-	-	-	-	-	-	-
	Unknown	4.5	0.0 - 9.1	4.7	0.0 - 9.5	-	-	6.9	0.7 - 13.0	7.5	0.8 - 14.2	-	-
<b>WEST Mountain</b>													
Colorado (NPCR)	All stages	11.5	8.7 - 14.3	11.3	8.3 - 14.4	6.9	0.0 - 15.0	16.0	13.2 - 18.9	15.6	12.6 - 18.6	11.0	1.5 - 20.5
	Localized	20.5	15.1 - 25.9	20.4	14.7 - 26.2	-	-	28.2	22.3 - 34.1	27.0	20.9 - 33.2	19.0	0.8 - 37.3
	Regional	7.7	3.5 - 12.0	7.6	3.1 - 12.1	0.0	-	6.4	3.2 - 9.6	5.9	2.7 - 9.0	15.2	0.0 - 34.1
	Distant	3.6	0.7 - 6.4	0.6	0.0 - 1.3	-	-	3.0	0.2 - 5.9	3.2	0.2 - 6.1	-	-
	Unknown	5.3	2.4 - 8.2	6.4	3.0 - 9.8	-	-	8.9	4.9 - 13.0	8.4	4.3 - 12.4	-	-
Idaho (NPCR)	All stages	15.4	8.1 - 22.6	15.2	7.7 - 22.7	-	-	11.5	6.5 - 16.4	11.8	6.6 - 17.1	-	-
	Localized	37.0	18.1 - 56.0	36.1	16.5 - 55.6	-	-	22.1	12.0 - 32.2	23.1	12.4 - 33.7	-	-
	Regional	4.0	0.0 - 10.0	4.0	0.0 - 10.0	-	-	6.9	0.0 - 15.1	6.9	0.0 - 15.1	-	-
	Distant	6.7	0.0 - 16.7	7.6	0.0 - 18.8	-	-	1.0	0.0 - 3.4	1.0	0.0 - 3.2	-	-
	Unknown	6.0	0.0 - 15.3	6.0	0.0 - 15.3	-	-	0.7	0.0 - 2.3	0.9	0.0 - 2.7	-	-
Montana (NPCR)	All stages	13.9	5.7 - 22.1	13.9	5.2 - 22.7	-	-	11.1	5.5 - 16.6	11.8	5.9 - 17.8	-	-
	Localized	27.3	7.9 - 46.7	32.1	10.0 - 54.3	-	-	16.4	6.1 - 26.8	16.4	5.8 - 26.9	-	-
	Regional	6.8	0.0 - 16.6	7.6	0.0 - 18.6	-	-	8.1	0.0 - 16.2	8.8	0.0 - 17.9	-	-
	Distant	-	-	-	-	-	-	-	-	-	-	-	-
	Unknown	13.0	0.6 - 25.4	10.1	0.0 - 21.7	-	-	21.3	2.2 - 40.4	20.8	0.6 - 41.1	-	-
New Mexico (SEER)	All stages	7.0	4.3 - 9.7	6.9	4.0 - 9.7	-	-	9.7	7.1 - 12.4	9.9	7.0 - 12.9	-	-
	Localized	11.5	6.5 - 16.4	11.6	6.3 - 16.9	-	-	17.0	11.6 - 22.3	15.9	10.6 - 21.3	-	-
	Regional	2.3	0.0 - 5.6	0.0	-	-	-	0.0	0.0 - 0.0	2.2	0.0 - 5.2	-	-
	Distant	4.8	0.8 - 8.9	4.9	0.9 - 8.9	-	-	5.5	1.3 - 9.6	4.6	0.5 - 8.7	-	-
	Unknown	3.0	0.0 - 6.2	3.3	0.0 - 6.8	-	-	6.8	2.4 - 11.2	6.6	1.9 - 11.3	-	-
Utah (SEER)	All stages	11.4	6.5 - 16.3	11.7	6.5 - 17.0	-	-	9.8	5.9 - 13.7	10.7	6.4 - 15.0	-	-
	Localized	16.8	9.6 - 24.1	18.8	10.5 - 27.2	-	-	23.9	17.3 - 30.5	23.0	16.1 - 29.8	-	-
	Regional	12.5	1.8 - 23.2	8.9	0.0 - 19.2	-	-	2.9	0.0 - 7.4	3.4	0.0 - 8.8	-	-
	Distant	0.0	-	0.0	-	-	-	1.0	0.0 - 3.4	1.2	0.0 - 4.0	-	-
	Unknown	5.5	0.0 - 13.9	6.1	0.0 - 15.4	-	-	0.0	-	0.0	-	-	-
Wyoming (NPCR)	All stages	2.7	0.0 - 7.0	3.0	0.0 - 7.6	-	-	8.1	2.2 - 13.9	8.1	2.3 - 14.0	-	-
	Localized	-	-	-	-	-	-	15.9	5.3 - 26.6	15.7	5.2 - 26.3	-	-
	Regional	-	-	-	-	-	-	-	-	-	-	-	-
	Distant	-	-	-	-	-	-	-	-	0.0	-	-	-
	Unknown	0.0	-	0.0	-	-	-	6.5	0.0 - 15.9	6.8	0.0 - 16.6	-	-
<b>Pacific</b>													
Alaska (NPCR)	All stages	9.0	3.9 - 14.0	9.8	2.6 - 17.0	-	-	16.6	9.4 - 23.7	13.1	6.9 - 19.4	-	-
	Localized	26.1	10.1 - 42.0	22.0	2.0 - 42.0	-	-	34.8	20.4 - 49.2	46.1	29.1 - 63.2	-	-
	Regional	4.6	0.0 - 11.6	7.8	0.0 - 19.4	-	-	3.0	0.0 - 7.5	4.8	0.0 - 12.0	-	-
	Distant	5.6	0.0 - 14.1	10.0	0.0 - 24.6	-	-	0.0	0.0 - 0.0	0.1	0.0 - 0.5	-	-
	Unknown	7.5	0.0 - 16.2	4.1	0.0 - 10.4	-	-	10.0	0.0 - 21.9	0.0	0.0 - 0.0	-	-
California (NPCR/SEER)	All stages	11.4	10.6 - 12.3	10.1	9.1 - 11.1	7.2	5.1 - 9.3	14.8	13.8 - 15.8	12.8	11.7 - 13.9	11.7	8.5 - 14.9
	Localized	21.8	20.0 - 23.6	18.9	16.8 - 20.9	13.9	9.1 - 18.7	26.1	24.1 - 28.0	22.6	20.4 - 24.8	25.1	19.0 - 31.3
	Regional	7.8	6.4 - 9.2	7.5	5.7 - 9.3	5.0	2.1 - 7.8	10.1	8.6 - 11.6	8.8	7.1 - 10.4	5.9	2.3 - 9.5
	Distant	1.9	1.1 - 2.6	1.8	0.9 - 2.8	3.4	0.0 - 7.0	1.7	1.0 - 2.4	1.4	0.7 - 2.1	3.3	0.7 - 5.9
	Unknown	3.8	2.5 - 5.1	3.9	2.3 - 5.5	1.1	0.0 - 2.4	5.8	4.2 - 7.3	5.5	3.7 - 7.3	4.4	0.0 - 10.3
Hawaii (SEER)	All stages	15.2	11.3 - 19.1	19.8	8.4 - 31.1	-	-	13.2	8.8 - 17.6	16.8	9.0 - 24.7	21.8	0.0 - 44.9
	Localized	31.4	23.9 - 38.9	43.2	21.5 - 65.0	-	-	27.0	18.7 - 35.3	31.4	11.1 - 51.6	-	-
	Regional	6.9	2.7 - 11.2	5.9	0.0 - 14.9	-	-	4.5	0.0 - 10.0	11.6	1.4 - 21.8	-	-
	Distant	1.0	0.0 - 2.1	-	-	-	-	1.4	0.0 - 3.4	5.4	0.0 - 12.7	-	-
	Unknown	0.0	-	-	-	-	-	0.1	0.0 - 0.3	7.5	0.0 - 18.2	-	-

Cancer

SEER Summary Stage	2001-2003						2004-2009						
	All races		White		Black		All races		White		Black		
	NS (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI	NS (%)	95% CI	
Oregon (NPCR)	All stages	6.9	4.3 - 9.5	5.9	3.3 - 8.5	-	-	11.2	8.7 - 13.8	10.1	7.4 - 12.8	6.3	0.0 - 15.3
	Localized	13.4	6.8 - 20.0	10.5	4.2 - 16.8	-	-	22.8	16.9 - 28.7	20.0	14.0 - 26.0	0.0	0.0 - 0.1
	Regional	8.0	2.6 - 13.3	10.1	3.5 - 16.8	-	-	7.9	4.5 - 11.3	7.2	3.6 - 10.7	0.1	0.0 - 0.2
	Distant	1.9	0.0 - 4.0	2.2	0.0 - 4.5	-	-	2.8	0.1 - 5.4	3.9	0.7 - 7.0	-	-
	Unknown	3.6	0.7 - 6.5	2.0	0.0 - 4.1	-	-	4.2	0.5 - 8.0	3.7	0.4 - 7.0	-	-
Washington (NPCR)	All stages	11.8	9.5 - 14.1	10.7	8.1 - 13.2	12.3	1.6 - 23.1	14.7	12.4 - 17.0	13.9	11.3 - 16.4	8.1	4.6 - 11.7
	Localized	23.9	18.9 - 28.8	24.4	18.7 - 30.1	22.9	1.7 - 44.0	28.1	23.1 - 33.0	28.2	22.7 - 33.7	13.2	0.0 - 27.5
	Regional	6.4	3.5 - 9.4	4.1	1.5 - 6.6	6.8	0.0 - 17.0	7.4	4.8 - 10.1	5.3	2.9 - 7.8	5.5	0.0 - 12.9
	Distant	1.9	0.3 - 3.6	1.6	0.1 - 3.1	-	-	0.9	0.0 - 2.2	1.2	0.0 - 2.7	-	-
	Unknown	1.5	0.0 - 3.0	1.8	0.0 - 3.6	-	-	5.6	2.4 - 8.9	5.1	1.7 - 8.5	-	-

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60